id	sid	tid	token	lemma	pos
dti-2637	1	1	dti	dti	PROPN
dti-2637	1	2	drug	drug	PROPN
dti-2637	1	3	target	target	NOUN
dti-2637	1	4	insights	insight	NOUN
dti-2637	1	5	2024	2024	NUM
dti-2637	1	6	;	;	PUNCT
dti-2637	1	7	18	18	NUM
dti-2637	1	8	:	:	SYM
dti-2637	1	9	4	4	NUM
dti-2637	1	10	-	-	SYM
dti-2637	1	11	7	7	NUM
dti-2637	1	12	issn	issn	PROPN
dti-2637	1	13	1177	1177	NUM
dti-2637	1	14	-	-	SYM
dti-2637	1	15	3928	3928	NUM
dti-2637	1	16	|	|	ADV
dti-2637	1	17	doi	doi	NOUN
dti-2637	1	18	:	:	PUNCT
dti-2637	1	19	10.33393	10.33393	NUM
dti-2637	1	20	/	/	SYM
dti-2637	1	21	dti.2024.2637	dti.2024.2637	PROPN
dti-2637	1	22	case	case	NOUN
dti-2637	1	23	report	report	NOUN
dti-2637	1	24	drug	drug	NOUN
dti-2637	1	25	target	target	NOUN
dti-2637	1	26	insights	insight	NOUN
dti-2637	1	27	issn	issn	VERB
dti-2637	1	28	1177	1177	NUM
dti-2637	1	29	-	-	SYM
dti-2637	1	30	3928	3928	NUM
dti-2637	1	31	www.aboutscience.eu/dti	www.aboutscience.eu/dti	NOUN
dti-2637	1	32	©	©	PROPN
dti-2637	1	33	2024	2024	NUM
dti-2637	1	34	the	the	DET
dti-2637	1	35	authors	author	NOUN
dti-2637	1	36	.	.	PUNCT
dti-2637	2	1	this	this	DET
dti-2637	2	2	article	article	NOUN
dti-2637	2	3	is	be	AUX
dti-2637	2	4	published	publish	VERB
dti-2637	2	5	by	by	ADP
dti-2637	2	6	aboutscience	aboutscience	NOUN
dti-2637	2	7	and	and	CCONJ
dti-2637	2	8	licensed	license	VERB
dti-2637	2	9	under	under	ADP
dti-2637	2	10	creative	creative	ADJ
dti-2637	2	11	commons	common	NOUN
dti-2637	2	12	attribution	attribution	NOUN
dti-2637	2	13	-	-	PUNCT
dti-2637	2	14	noncommercial	noncommercial	ADJ
dti-2637	2	15	4.0	4.0	NUM
dti-2637	2	16	international	international	NOUN
dti-2637	2	17	(	(	PUNCT
dti-2637	2	18	cc	cc	NOUN
dti-2637	2	19	by	by	ADP
dti-2637	2	20	-	-	PUNCT
dti-2637	2	21	nc	nc	PROPN
dti-2637	2	22	4.0	4.0	NUM
dti-2637	2	23	)	)	PUNCT
dti-2637	2	24	.	.	PUNCT
dti-2637	3	1	commercial	commercial	ADJ
dti-2637	3	2	use	use	NOUN
dti-2637	3	3	is	be	AUX
dti-2637	3	4	not	not	PART
dti-2637	3	5	permitted	permit	VERB
dti-2637	3	6	and	and	CCONJ
dti-2637	3	7	is	be	AUX
dti-2637	3	8	subject	subject	ADJ
dti-2637	3	9	to	to	ADP
dti-2637	3	10	publisher	publisher	NOUN
dti-2637	3	11	’s	’s	PART
dti-2637	3	12	permissions	permission	NOUN
dti-2637	3	13	.	.	PUNCT
dti-2637	4	1	full	full	ADJ
dti-2637	4	2	information	information	NOUN
dti-2637	4	3	is	be	AUX
dti-2637	4	4	available	available	ADJ
dti-2637	4	5	at	at	ADP
dti-2637	4	6	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2637	4	7	long	long	ADJ
dti-2637	4	8	-	-	PUNCT
dti-2637	4	9	term	term	NOUN
dti-2637	4	10	response	response	NOUN
dti-2637	4	11	with	with	ADP
dti-2637	4	12	the	the	DET
dti-2637	4	13	atypical	atypical	ADJ
dti-2637	4	14	reaction	reaction	NOUN
dti-2637	4	15	to	to	ADP
dti-2637	4	16	nivolumab	nivolumab	NOUN
dti-2637	4	17	in	in	ADP
dti-2637	4	18	microsatellite	microsatellite	ADJ
dti-2637	4	19	stability	stability	NOUN
dti-2637	4	20	metastatic	metastatic	ADJ
dti-2637	4	21	colorectal	colorectal	ADJ
dti-2637	4	22	cancer	cancer	NOUN
dti-2637	4	23	:	:	PUNCT
dti-2637	4	24	a	a	DET
dti-2637	4	25	case	case	NOUN
dti-2637	4	26	report	report	VERB
dti-2637	4	27	nataliya	nataliya	PROPN
dti-2637	5	1	babyshkina1,2	babyshkina1,2	PROPN
dti-2637	5	2	,	,	PUNCT
dti-2637	5	3	nataliya	nataliya	PROPN
dti-2637	5	4	popova3	popova3	PROPN
dti-2637	5	5	,	,	PUNCT
dti-2637	5	6	evgeny	evgeny	PROPN
dti-2637	5	7	grigoryev4	grigoryev4	PROPN
dti-2637	5	8	,	,	PUNCT
dti-2637	5	9	tatyana	tatyana	PROPN
dti-2637	5	10	dronova1	dronova1	PROPN
dti-2637	5	11	,	,	PUNCT
dti-2637	5	12	polina	polina	PROPN
dti-2637	5	13	gervas1	gervas1	PROPN
dti-2637	5	14	,	,	PUNCT
dti-2637	5	15	alexey	alexey	PROPN
dti-2637	5	16	dobrodeev5	dobrodeev5	PROPN
dti-2637	5	17	,	,	PUNCT
dti-2637	5	18	dmitry	dmitry	PROPN
dti-2637	5	19	kostromitskiy5	kostromitskiy5	PROPN
dti-2637	5	20	,	,	PUNCT
dti-2637	5	21	victor	victor	PROPN
dti-2637	5	22	goldberg3	goldberg3	PROPN
dti-2637	5	23	,	,	PUNCT
dti-2637	5	24	sergey	sergey	PROPN
dti-2637	5	25	afanasiev5	afanasiev5	PROPN
dti-2637	5	26	,	,	PUNCT
dti-2637	5	27	nadejda	nadejda	NOUN
dti-2637	5	28	cherdyntseva1	cherdyntseva1	NOUN
dti-2637	6	1	1department	1department	NUM
dti-2637	6	2	of	of	ADP
dti-2637	6	3	molecular	molecular	ADJ
dti-2637	6	4	oncology	oncology	NOUN
dti-2637	6	5	and	and	CCONJ
dti-2637	6	6	immunology	immunology	NOUN
dti-2637	6	7	,	,	PUNCT
dti-2637	6	8	cancer	cancer	NOUN
dti-2637	6	9	research	research	PROPN
dti-2637	6	10	institute	institute	PROPN
dti-2637	6	11	,	,	PUNCT
dti-2637	6	12	tomsk	tomsk	PROPN
dti-2637	6	13	national	national	PROPN
dti-2637	6	14	research	research	PROPN
dti-2637	6	15	medical	medical	ADJ
dti-2637	6	16	center	center	NOUN
dti-2637	6	17	,	,	PUNCT
dti-2637	6	18	russian	russian	ADJ
dti-2637	6	19	academy	academy	PROPN
dti-2637	6	20	of	of	ADP
dti-2637	6	21	sciences	sciences	PROPN
dti-2637	6	22	,	,	PUNCT
dti-2637	6	23	tomsk	tomsk	PROPN
dti-2637	6	24	russian	russian	PROPN
dti-2637	6	25	federation	federation	PROPN
dti-2637	7	1	2siberian	2siberian	NUM
dti-2637	7	2	state	state	NOUN
dti-2637	7	3	medical	medical	ADJ
dti-2637	7	4	university	university	NOUN
dti-2637	7	5	,	,	PUNCT
dti-2637	7	6	tomsk	tomsk	PROPN
dti-2637	7	7	russian	russian	PROPN
dti-2637	7	8	federation	federation	PROPN
dti-2637	7	9	3department	3department	NUM
dti-2637	7	10	of	of	ADP
dti-2637	7	11	chemotherapy	chemotherapy	NOUN
dti-2637	7	12	,	,	PUNCT
dti-2637	7	13	cancer	cancer	NOUN
dti-2637	7	14	research	research	PROPN
dti-2637	7	15	institute	institute	PROPN
dti-2637	7	16	,	,	PUNCT
dti-2637	7	17	tomsk	tomsk	PROPN
dti-2637	7	18	national	national	PROPN
dti-2637	7	19	research	research	PROPN
dti-2637	7	20	medical	medical	ADJ
dti-2637	7	21	center	center	NOUN
dti-2637	7	22	,	,	PUNCT
dti-2637	7	23	russian	russian	ADJ
dti-2637	7	24	academy	academy	PROPN
dti-2637	7	25	of	of	ADP
dti-2637	7	26	sciences	sciences	PROPN
dti-2637	7	27	,	,	PUNCT
dti-2637	7	28	tomsk	tomsk	PROPN
dti-2637	7	29	russian	russian	PROPN
dti-2637	7	30	federation	federation	PROPN
dti-2637	7	31	4department	4department	NUM
dti-2637	7	32	of	of	ADP
dti-2637	7	33	diagnostic	diagnostic	ADJ
dti-2637	7	34	imaging	imaging	NOUN
dti-2637	7	35	,	,	PUNCT
dti-2637	7	36	cancer	cancer	NOUN
dti-2637	7	37	research	research	PROPN
dti-2637	7	38	institute	institute	PROPN
dti-2637	7	39	,	,	PUNCT
dti-2637	7	40	tomsk	tomsk	PROPN
dti-2637	7	41	national	national	PROPN
dti-2637	7	42	research	research	PROPN
dti-2637	7	43	medical	medical	ADJ
dti-2637	7	44	center	center	NOUN
dti-2637	7	45	,	,	PUNCT
dti-2637	7	46	russian	russian	ADJ
dti-2637	7	47	academy	academy	PROPN
dti-2637	7	48	of	of	ADP
dti-2637	7	49	sciences	sciences	PROPN
dti-2637	7	50	,	,	PUNCT
dti-2637	7	51	tomsk	tomsk	PROPN
dti-2637	7	52	russian	russian	PROPN
dti-2637	7	53	federation	federation	PROPN
dti-2637	7	54	5department	5department	NUM
dti-2637	7	55	of	of	ADP
dti-2637	7	56	abdominal	abdominal	ADJ
dti-2637	7	57	oncology	oncology	NOUN
dti-2637	7	58	,	,	PUNCT
dti-2637	7	59	cancer	cancer	NOUN
dti-2637	7	60	research	research	PROPN
dti-2637	7	61	institute	institute	PROPN
dti-2637	7	62	,	,	PUNCT
dti-2637	7	63	tomsk	tomsk	PROPN
dti-2637	7	64	national	national	PROPN
dti-2637	7	65	research	research	PROPN
dti-2637	7	66	medical	medical	ADJ
dti-2637	7	67	center	center	NOUN
dti-2637	7	68	,	,	PUNCT
dti-2637	7	69	russian	russian	ADJ
dti-2637	7	70	academy	academy	PROPN
dti-2637	7	71	of	of	ADP
dti-2637	7	72	sciences	sciences	PROPN
dti-2637	7	73	,	,	PUNCT
dti-2637	7	74	tomsk	tomsk	PROPN
dti-2637	7	75	russian	russian	PROPN
dti-2637	7	76	federation	federation	PROPN
dti-2637	7	77	abstract	abstract	ADJ
dti-2637	7	78	immunotherapy	immunotherapy	NOUN
dti-2637	7	79	has	have	AUX
dti-2637	7	80	become	become	VERB
dti-2637	7	81	an	an	DET
dti-2637	7	82	integral	integral	ADJ
dti-2637	7	83	part	part	NOUN
dti-2637	7	84	of	of	ADP
dti-2637	7	85	a	a	DET
dti-2637	7	86	comprehensive	comprehensive	ADJ
dti-2637	7	87	treatment	treatment	NOUN
dti-2637	7	88	approach	approach	NOUN
dti-2637	7	89	to	to	ADP
dti-2637	7	90	metastatic	metastatic	VERB
dti-2637	7	91	colorectal	colorectal	ADJ
dti-2637	7	92	cancer	cancer	NOUN
dti-2637	7	93	(	(	PUNCT
dti-2637	7	94	mcrc	mcrc	NOUN
dti-2637	7	95	)	)	PUNCT
dti-2637	7	96	.	.	PUNCT
dti-2637	8	1	nivolumab	nivolumab	NOUN
dti-2637	8	2	(	(	PUNCT
dti-2637	8	3	opdivo	opdivo	PROPN
dti-2637	8	4	)	)	PUNCT
dti-2637	8	5	is	be	AUX
dti-2637	8	6	a	a	DET
dti-2637	8	7	human	human	ADJ
dti-2637	8	8	immunoglobulin	immunoglobulin	NOUN
dti-2637	8	9	g4	g4	NOUN
dti-2637	8	10	monoclonal	monoclonal	NOUN
dti-2637	8	11	antibody	antibody	NOUN
dti-2637	8	12	that	that	PRON
dti-2637	8	13	blocks	block	VERB
dti-2637	8	14	the	the	DET
dti-2637	8	15	interaction	interaction	NOUN
dti-2637	8	16	between	between	ADP
dti-2637	8	17	the	the	DET
dti-2637	8	18	programmed	program	VERB
dti-2637	8	19	cell	cell	NOUN
dti-2637	8	20	death	death	NOUN
dti-2637	8	21	1	1	NUM
dti-2637	8	22	(	(	PUNCT
dti-2637	8	23	pd-1	pd-1	NOUN
dti-2637	8	24	)	)	PUNCT
dti-2637	8	25	receptor	receptor	NOUN
dti-2637	8	26	and	and	CCONJ
dti-2637	8	27	its	its	PRON
dti-2637	8	28	ligands	ligand	NOUN
dti-2637	8	29	1/2	1/2	NUM
dti-2637	8	30	(	(	PUNCT
dti-2637	8	31	pd	pd	NOUN
dti-2637	8	32	-	-	PUNCT
dti-2637	8	33	l1	l1	PROPN
dti-2637	8	34	/	/	SYM
dti-2637	8	35	pd	pd	NOUN
dti-2637	8	36	-	-	PUNCT
dti-2637	8	37	l2	l2	NOUN
dti-2637	8	38	)	)	PUNCT
dti-2637	8	39	,	,	PUNCT
dti-2637	8	40	leading	lead	VERB
dti-2637	8	41	to	to	ADP
dti-2637	8	42	inhibition	inhibition	NOUN
dti-2637	8	43	of	of	ADP
dti-2637	8	44	t	t	NOUN
dti-2637	8	45	-	-	PUNCT
dti-2637	8	46	cell	cell	NOUN
dti-2637	8	47	proliferation	proliferation	NOUN
dti-2637	8	48	,	,	PUNCT
dti-2637	8	49	cytokine	cytokine	ADJ
dti-2637	8	50	secretion	secretion	NOUN
dti-2637	8	51	,	,	PUNCT
dti-2637	8	52	and	and	CCONJ
dti-2637	8	53	enhanced	enhance	VERB
dti-2637	8	54	immune	immune	ADJ
dti-2637	8	55	response	response	NOUN
dti-2637	8	56	.	.	PUNCT
dti-2637	9	1	the	the	DET
dti-2637	9	2	us	us	PROPN
dti-2637	9	3	food	food	NOUN
dti-2637	9	4	and	and	CCONJ
dti-2637	9	5	drug	drug	PROPN
dti-2637	9	6	administration	administration	PROPN
dti-2637	9	7	(	(	PUNCT
dti-2637	9	8	fda	fda	PROPN
dti-2637	9	9	)	)	PUNCT
dti-2637	9	10	has	have	AUX
dti-2637	9	11	approved	approve	VERB
dti-2637	9	12	this	this	DET
dti-2637	9	13	drug	drug	NOUN
dti-2637	9	14	for	for	ADP
dti-2637	9	15	use	use	NOUN
dti-2637	9	16	in	in	ADP
dti-2637	9	17	high	high	ADJ
dti-2637	9	18	microsatellite	microsatellite	NOUN
dti-2637	9	19	instability	instability	NOUN
dti-2637	9	20	(	(	PUNCT
dti-2637	9	21	msi	msi	PROPN
dti-2637	9	22	-	-	NOUN
dti-2637	9	23	high)/deficiencies	high)/deficiencie	NOUN
dti-2637	9	24	in	in	ADP
dti-2637	9	25	mismatch	mismatch	ADJ
dti-2637	9	26	repair	repair	NOUN
dti-2637	9	27	(	(	PUNCT
dti-2637	9	28	dmmr	dmmr	NOUN
dti-2637	9	29	)	)	PUNCT
dti-2637	9	30	advanced	advanced	ADJ
dti-2637	9	31	crc	crc	NOUN
dti-2637	9	32	patients	patient	NOUN
dti-2637	9	33	.	.	PUNCT
dti-2637	10	1	however	however	ADV
dti-2637	10	2	,	,	PUNCT
dti-2637	10	3	its	its	PRON
dti-2637	10	4	efficacy	efficacy	NOUN
dti-2637	10	5	is	be	AUX
dti-2637	10	6	extremely	extremely	ADV
dti-2637	10	7	limited	limited	ADJ
dti-2637	10	8	in	in	ADP
dti-2637	10	9	microsatellite	microsatellite	ADJ
dti-2637	10	10	stability	stability	NOUN
dti-2637	10	11	(	(	PUNCT
dti-2637	10	12	mss)/mismatch	mss)/mismatch	NOUN
dti-2637	10	13	repair	repair	NOUN
dti-2637	10	14	proficient	proficient	ADJ
dti-2637	10	15	(	(	PUNCT
dti-2637	10	16	pmmr	pmmr	NOUN
dti-2637	10	17	)	)	PUNCT
dti-2637	10	18	patients	patient	NOUN
dti-2637	10	19	.	.	PUNCT
dti-2637	11	1	we	we	PRON
dti-2637	11	2	report	report	VERB
dti-2637	11	3	a	a	DET
dti-2637	11	4	case	case	NOUN
dti-2637	11	5	of	of	ADP
dti-2637	11	6	a	a	DET
dti-2637	11	7	42	42	NUM
dti-2637	11	8	-	-	PUNCT
dti-2637	11	9	year	year	NOUN
dti-2637	11	10	-	-	PUNCT
dti-2637	11	11	old	old	ADJ
dti-2637	11	12	man	man	NOUN
dti-2637	11	13	diagnosed	diagnose	VERB
dti-2637	11	14	with	with	ADP
dti-2637	11	15	mss	mss	PROPN
dti-2637	11	16	/	/	SYM
dti-2637	11	17	pmmr	pmmr	PROPN
dti-2637	11	18	mcrc	mcrc	NOUN
dti-2637	11	19	who	who	PRON
dti-2637	11	20	has	have	AUX
dti-2637	11	21	achieved	achieve	VERB
dti-2637	11	22	a	a	DET
dti-2637	11	23	durable	durable	ADJ
dti-2637	11	24	response	response	NOUN
dti-2637	11	25	to	to	ADP
dti-2637	11	26	nivolumab	nivolumab	NOUN
dti-2637	11	27	after	after	ADP
dti-2637	11	28	a	a	DET
dti-2637	11	29	progression	progression	NOUN
dti-2637	11	30	under	under	ADP
dti-2637	11	31	chemotherapy	chemotherapy	NOUN
dti-2637	11	32	with	with	ADP
dti-2637	11	33	antiangiogenic	antiangiogenic	ADJ
dti-2637	11	34	treatment	treatment	NOUN
dti-2637	11	35	.	.	PUNCT
dti-2637	12	1	we	we	PRON
dti-2637	12	2	observed	observe	VERB
dti-2637	12	3	for	for	ADP
dti-2637	12	4	the	the	DET
dti-2637	12	5	first	first	ADJ
dti-2637	12	6	time	time	NOUN
dti-2637	12	7	an	an	DET
dti-2637	12	8	atypical	atypical	ADJ
dti-2637	12	9	response	response	NOUN
dti-2637	12	10	after	after	ADP
dti-2637	12	11	8	8	NUM
dti-2637	12	12	months	month	NOUN
dti-2637	12	13	of	of	ADP
dti-2637	12	14	nivolumab	nivolumab	NOUN
dti-2637	12	15	treatment	treatment	NOUN
dti-2637	12	16	,	,	PUNCT
dti-2637	12	17	with	with	ADP
dti-2637	12	18	the	the	DET
dti-2637	12	19	regression	regression	NOUN
dti-2637	12	20	of	of	ADP
dti-2637	12	21	previous	previous	ADJ
dti-2637	12	22	primary	primary	ADJ
dti-2637	12	23	pulmonary	pulmonary	ADJ
dti-2637	12	24	lesions	lesion	NOUN
dti-2637	12	25	and	and	CCONJ
dti-2637	12	26	the	the	DET
dti-2637	12	27	presence	presence	NOUN
dti-2637	12	28	of	of	ADP
dti-2637	12	29	new	new	ADJ
dti-2637	12	30	para	para	NOUN
dti-2637	12	31	-	-	PUNCT
dti-2637	12	32	aortic	aortic	ADJ
dti-2637	12	33	lymph	lymph	NOUN
dti-2637	12	34	node	node	NOUN
dti-2637	12	35	lesions	lesion	NOUN
dti-2637	12	36	.	.	PUNCT
dti-2637	13	1	this	this	DET
dti-2637	13	2	report	report	NOUN
dti-2637	13	3	demonstrates	demonstrate	VERB
dti-2637	13	4	that	that	SCONJ
dti-2637	13	5	a	a	DET
dti-2637	13	6	subset	subset	NOUN
dti-2637	13	7	of	of	ADP
dti-2637	13	8	pretreated	pretreate	VERB
dti-2637	13	9	mcrc	mcrc	NOUN
dti-2637	13	10	patients	patient	NOUN
dti-2637	13	11	with	with	ADP
dti-2637	13	12	the	the	DET
dti-2637	13	13	mss	mss	PROPN
dti-2637	13	14	/	/	SYM
dti-2637	13	15	pmmr	pmmr	ADJ
dti-2637	13	16	phenotype	phenotype	NOUN
dti-2637	13	17	may	may	AUX
dti-2637	13	18	benefit	benefit	VERB
dti-2637	13	19	from	from	ADP
dti-2637	13	20	nivolumab	nivolumab	NOUN
dti-2637	13	21	and	and	CCONJ
dti-2637	13	22	these	these	DET
dti-2637	13	23	patients	patient	NOUN
dti-2637	13	24	need	need	VERB
dti-2637	13	25	more	more	ADJ
dti-2637	13	26	attention	attention	NOUN
dti-2637	13	27	.	.	PUNCT
dti-2637	14	1	keywords	keyword	NOUN
dti-2637	14	2	:	:	PUNCT
dti-2637	14	3	dissociated	dissociate	VERB
dti-2637	14	4	response	response	NOUN
dti-2637	14	5	,	,	PUNCT
dti-2637	14	6	irecist	irecist	NOUN
dti-2637	14	7	,	,	PUNCT
dti-2637	14	8	metastatic	metastatic	ADJ
dti-2637	14	9	colorectal	colorectal	ADJ
dti-2637	14	10	cancer	cancer	NOUN
dti-2637	14	11	,	,	PUNCT
dti-2637	14	12	microsatellite	microsatellite	ADJ
dti-2637	14	13	stability	stability	NOUN
dti-2637	14	14	,	,	PUNCT
dti-2637	14	15	nivolumab	nivolumab	ADV
dti-2637	14	16	received	receive	VERB
dti-2637	14	17	:	:	PUNCT
dti-2637	14	18	july	july	PROPN
dti-2637	14	19	19	19	NUM
dti-2637	14	20	,	,	PUNCT
dti-2637	14	21	2023	2023	NUM
dti-2637	14	22	accepted	accept	VERB
dti-2637	14	23	:	:	PUNCT
dti-2637	14	24	january	january	PROPN
dti-2637	14	25	8	8	NUM
dti-2637	14	26	,	,	PUNCT
dti-2637	14	27	2024	2024	NUM
dti-2637	14	28	published	publish	VERB
dti-2637	14	29	online	online	ADV
dti-2637	14	30	:	:	PUNCT
dti-2637	14	31	january	january	PROPN
dti-2637	14	32	23	23	NUM
dti-2637	14	33	,	,	PUNCT
dti-2637	14	34	2024	2024	NUM
dti-2637	14	35	corresponding	correspond	VERB
dti-2637	14	36	author	author	NOUN
dti-2637	14	37	:	:	PUNCT
dti-2637	14	38	nataliya	nataliya	PROPN
dti-2637	14	39	babyshkina	babyshkina	PROPN
dti-2637	14	40	nbabyshkina@mail.ru	nbabyshkina@mail.ru	PROPN
dti-2637	14	41	instability	instability	NOUN
dti-2637	14	42	(	(	PUNCT
dti-2637	14	43	msi	msi	NOUN
dti-2637	14	44	-	-	ADJ
dti-2637	14	45	high	high	ADJ
dti-2637	14	46	)	)	PUNCT
dti-2637	14	47	and	and	CCONJ
dti-2637	14	48	have	have	AUX
dti-2637	14	49	progressed	progress	VERB
dti-2637	14	50	after	after	ADP
dti-2637	14	51	conventional	conventional	ADJ
dti-2637	14	52	chemotherapy	chemotherapy	NOUN
dti-2637	14	53	.	.	PUNCT
dti-2637	15	1	the	the	DET
dti-2637	15	2	nivolumab	nivolumab	NOUN
dti-2637	15	3	action	action	NOUN
dti-2637	15	4	is	be	AUX
dti-2637	15	5	directed	direct	VERB
dti-2637	15	6	at	at	ADP
dti-2637	15	7	the	the	DET
dti-2637	15	8	programmed	program	VERB
dti-2637	15	9	cell	cell	NOUN
dti-2637	15	10	death	death	NOUN
dti-2637	15	11	1	1	NUM
dti-2637	15	12	(	(	PUNCT
dti-2637	15	13	pd-1	pd-1	NOUN
dti-2637	15	14	)	)	PUNCT
dti-2637	15	15	receptor	receptor	NOUN
dti-2637	15	16	,	,	PUNCT
dti-2637	15	17	a	a	DET
dti-2637	15	18	member	member	NOUN
dti-2637	15	19	of	of	ADP
dti-2637	15	20	the	the	DET
dti-2637	15	21	cd28	cd28	PROPN
dti-2637	15	22	superfamily	superfamily	NOUN
dti-2637	15	23	,	,	PUNCT
dti-2637	15	24	which	which	PRON
dti-2637	15	25	is	be	AUX
dti-2637	15	26	expressed	express	VERB
dti-2637	15	27	on	on	ADP
dti-2637	15	28	the	the	DET
dti-2637	15	29	surface	surface	NOUN
dti-2637	15	30	of	of	ADP
dti-2637	15	31	activated	activate	VERB
dti-2637	15	32	t	t	PROPN
dti-2637	15	33	and	and	CCONJ
dti-2637	15	34	b	b	PROPN
dti-2637	15	35	lymphocytes	lymphocyte	NOUN
dti-2637	15	36	.	.	PUNCT
dti-2637	16	1	activation	activation	NOUN
dti-2637	16	2	of	of	ADP
dti-2637	16	3	pd-1	pd-1	ADV
dti-2637	16	4	/	/	SYM
dti-2637	16	5	programmed	program	VERB
dti-2637	16	6	cell	cell	NOUN
dti-2637	16	7	death	death	NOUN
dti-2637	16	8	ligands	ligand	NOUN
dti-2637	16	9	1/2	1/2	NUM
dti-2637	16	10	(	(	PUNCT
dti-2637	16	11	pd	pd	NOUN
dti-2637	16	12	-	-	PUNCT
dti-2637	16	13	l1	l1	PROPN
dti-2637	16	14	/	/	SYM
dti-2637	16	15	pd	pd	NOUN
dti-2637	16	16	-	-	PUNCT
dti-2637	16	17	l2	l2	NOUN
dti-2637	16	18	)	)	PUNCT
dti-2637	16	19	on	on	ADP
dti-2637	16	20	the	the	DET
dti-2637	16	21	tumor	tumor	NOUN
dti-2637	16	22	and	and	CCONJ
dti-2637	16	23	the	the	DET
dti-2637	16	24	tumor	tumor	NOUN
dti-2637	16	25	microenvironment	microenvironment	NOUN
dti-2637	16	26	leads	lead	VERB
dti-2637	16	27	to	to	ADP
dti-2637	16	28	enhanced	enhance	VERB
dti-2637	16	29	immunosuppressive	immunosuppressive	ADJ
dti-2637	16	30	effects	effect	NOUN
dti-2637	16	31	(	(	PUNCT
dti-2637	16	32	1	1	NUM
dti-2637	16	33	)	)	PUNCT
dti-2637	16	34	.	.	PUNCT
dti-2637	17	1	nivolumab	nivolumab	PROPN
dti-2637	17	2	binds	bind	VERB
dti-2637	17	3	to	to	ADP
dti-2637	17	4	the	the	DET
dti-2637	17	5	pd-1	pd-1	ADJ
dti-2637	17	6	receptor	receptor	NOUN
dti-2637	17	7	and	and	CCONJ
dti-2637	17	8	blocks	block	VERB
dti-2637	17	9	its	its	PRON
dti-2637	17	10	interaction	interaction	NOUN
dti-2637	17	11	with	with	ADP
dti-2637	17	12	pd	pd	PROPN
dti-2637	17	13	-	-	PROPN
dti-2637	17	14	l1	l1	PROPN
dti-2637	17	15	and	and	CCONJ
dti-2637	17	16	pd	pd	NOUN
dti-2637	17	17	-	-	NOUN
dti-2637	17	18	l2	l2	NOUN
dti-2637	17	19	,	,	PUNCT
dti-2637	17	20	inhibiting	inhibit	VERB
dti-2637	17	21	the	the	DET
dti-2637	17	22	pd-1mediated	pd-1mediate	VERB
dti-2637	17	23	immune	immune	ADJ
dti-2637	17	24	response	response	NOUN
dti-2637	17	25	.	.	PUNCT
dti-2637	18	1	nivolumab	nivolumab	NOUN
dti-2637	18	2	approval	approval	NOUN
dti-2637	18	3	was	be	AUX
dti-2637	18	4	based	base	VERB
dti-2637	18	5	on	on	ADP
dti-2637	18	6	data	datum	NOUN
dti-2637	18	7	from	from	ADP
dti-2637	18	8	checkmate	checkmate	VERB
dti-2637	18	9	142	142	NUM
dti-2637	18	10	multicenter	multicenter	NOUN
dti-2637	18	11	phase	phase	NOUN
dti-2637	18	12	2	2	NUM
dti-2637	18	13	study	study	NOUN
dti-2637	18	14	investigating	investigate	VERB
dti-2637	18	15	its	its	PRON
dti-2637	18	16	efficacy	efficacy	NOUN
dti-2637	18	17	and	and	CCONJ
dti-2637	18	18	safety	safety	NOUN
dti-2637	18	19	in	in	ADP
dti-2637	18	20	the	the	DET
dti-2637	18	21	cohort	cohort	NOUN
dti-2637	18	22	of	of	ADP
dti-2637	18	23	msi	msi	PROPN
dti-2637	18	24	-	-	ADJ
dti-2637	18	25	high	high	ADJ
dti-2637	18	26	/	/	SYM
dti-2637	18	27	dmmr	dmmr	ADV
dti-2637	18	28	mcrc	mcrc	NOUN
dti-2637	18	29	patients	patient	NOUN
dti-2637	18	30	who	who	PRON
dti-2637	18	31	had	have	AUX
dti-2637	18	32	progressed	progress	VERB
dti-2637	18	33	during	during	ADP
dti-2637	18	34	or	or	CCONJ
dti-2637	18	35	after	after	ADP
dti-2637	18	36	prior	prior	ADJ
dti-2637	18	37	treatment	treatment	NOUN
dti-2637	18	38	with	with	ADP
dti-2637	18	39	a	a	DET
dti-2637	18	40	fluoropyrimidine-	fluoropyrimidine-	ADJ
dti-2637	18	41	,	,	PUNCT
dti-2637	18	42	oxaliplatin-	oxaliplatin-	X
dti-2637	18	43	,	,	PUNCT
dti-2637	18	44	or	or	CCONJ
dti-2637	18	45	irinotecan	irinotecan	NOUN
dti-2637	18	46	-	-	PUNCT
dti-2637	18	47	based	base	VERB
dti-2637	18	48	chemotherapy	chemotherapy	NOUN
dti-2637	18	49	.	.	PUNCT
dti-2637	19	1	in	in	ADP
dti-2637	19	2	this	this	DET
dti-2637	19	3	study	study	NOUN
dti-2637	19	4	,	,	PUNCT
dti-2637	19	5	68.9	68.9	NUM
dti-2637	19	6	%	%	NOUN
dti-2637	19	7	of	of	ADP
dti-2637	19	8	patients	patient	NOUN
dti-2637	19	9	responded	respond	VERB
dti-2637	19	10	to	to	ADP
dti-2637	19	11	treatment	treatment	NOUN
dti-2637	19	12	,	,	PUNCT
dti-2637	19	13	with	with	ADP
dti-2637	19	14	31.1	31.1	NUM
dti-2637	19	15	%	%	NOUN
dti-2637	19	16	achieving	achieve	VERB
dti-2637	19	17	an	an	DET
dti-2637	19	18	objective	objective	ADJ
dti-2637	19	19	response	response	NOUN
dti-2637	19	20	rate	rate	NOUN
dti-2637	19	21	(	(	PUNCT
dti-2637	19	22	2	2	NUM
dti-2637	19	23	)	)	PUNCT
dti-2637	19	24	.	.	PUNCT
dti-2637	20	1	background	background	NOUN
dti-2637	20	2	immunotherapy	immunotherapy	NOUN
dti-2637	20	3	has	have	AUX
dti-2637	20	4	become	become	VERB
dti-2637	20	5	an	an	DET
dti-2637	20	6	integral	integral	ADJ
dti-2637	20	7	part	part	NOUN
dti-2637	20	8	of	of	ADP
dti-2637	20	9	a	a	DET
dti-2637	20	10	comprehensive	comprehensive	ADJ
dti-2637	20	11	treatment	treatment	NOUN
dti-2637	20	12	approach	approach	NOUN
dti-2637	20	13	to	to	ADP
dti-2637	20	14	metastatic	metastatic	VERB
dti-2637	20	15	colorectal	colorectal	ADJ
dti-2637	20	16	cancer	cancer	NOUN
dti-2637	20	17	(	(	PUNCT
dti-2637	20	18	mcrc	mcrc	NOUN
dti-2637	20	19	)	)	PUNCT
dti-2637	20	20	.	.	PUNCT
dti-2637	21	1	nivolumab	nivolumab	NOUN
dti-2637	21	2	,	,	PUNCT
dti-2637	21	3	one	one	NUM
dti-2637	21	4	of	of	ADP
dti-2637	21	5	the	the	DET
dti-2637	21	6	first	first	ADJ
dti-2637	21	7	immune	immune	ADJ
dti-2637	21	8	checkpoint	checkpoint	NOUN
dti-2637	21	9	inhibitors	inhibitor	NOUN
dti-2637	21	10	,	,	PUNCT
dti-2637	21	11	was	be	AUX
dti-2637	21	12	approved	approve	VERB
dti-2637	21	13	by	by	ADP
dti-2637	21	14	the	the	DET
dti-2637	21	15	us	us	PROPN
dti-2637	21	16	food	food	NOUN
dti-2637	21	17	and	and	CCONJ
dti-2637	21	18	drug	drug	PROPN
dti-2637	21	19	administration	administration	PROPN
dti-2637	21	20	(	(	PUNCT
dti-2637	21	21	fda	fda	PROPN
dti-2637	21	22	)	)	PUNCT
dti-2637	21	23	in	in	ADP
dti-2637	21	24	2017	2017	NUM
dti-2637	21	25	for	for	ADP
dti-2637	21	26	use	use	NOUN
dti-2637	21	27	in	in	ADP
dti-2637	21	28	patients	patient	NOUN
dti-2637	21	29	whose	whose	DET
dti-2637	21	30	tumors	tumor	NOUN
dti-2637	21	31	harbor	harbor	VERB
dti-2637	21	32	deficient	deficient	ADJ
dti-2637	21	33	mismatch	mismatch	PROPN
dti-2637	21	34	repair	repair	NOUN
dti-2637	21	35	(	(	PUNCT
dti-2637	21	36	dmmr	dmmr	NOUN
dti-2637	21	37	)	)	PUNCT
dti-2637	21	38	,	,	PUNCT
dti-2637	21	39	or	or	CCONJ
dti-2637	21	40	high	high	ADJ
dti-2637	21	41	microsatellite	microsatellite	NOUN
dti-2637	21	42	https://doi.org/10.33393/dti.2024.2637	https://doi.org/10.33393/dti.2024.2637	NOUN
dti-2637	21	43	https://doi.org/dti.2022.2522	https://doi.org/dti.2022.2522	PROPN
dti-2637	21	44	https://creativecommons.org/licenses/by-nc/4.0/legalcode	https://creativecommons.org/licenses/by-nc/4.0/legalcode	NUM
dti-2637	21	45	mailto:nbabyshkina@mail.ru	mailto:nbabyshkina@mail.ru	NOUN
dti-2637	21	46	babyshkina	babyshkina	NOUN
dti-2637	21	47	et	et	PROPN
dti-2637	21	48	al	al	PROPN
dti-2637	21	49	drug	drug	PROPN
dti-2637	21	50	target	target	NOUN
dti-2637	21	51	insights	insight	NOUN
dti-2637	21	52	2024	2024	NUM
dti-2637	21	53	;	;	PUNCT
dti-2637	21	54	18	18	NUM
dti-2637	21	55	:	:	SYM
dti-2637	21	56	5	5	NUM
dti-2637	21	57	©	©	PROPN
dti-2637	21	58	2024	2024	NUM
dti-2637	21	59	the	the	DET
dti-2637	21	60	authors	author	NOUN
dti-2637	21	61	.	.	PUNCT
dti-2637	22	1	published	publish	VERB
dti-2637	22	2	by	by	ADP
dti-2637	22	3	aboutscience	aboutscience	NOUN
dti-2637	22	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2637	22	5	further	further	ADJ
dti-2637	22	6	studies	study	NOUN
dti-2637	22	7	have	have	AUX
dti-2637	22	8	confirmed	confirm	VERB
dti-2637	22	9	that	that	SCONJ
dti-2637	22	10	nivolumab	nivolumab	NOUN
dti-2637	22	11	provides	provide	VERB
dti-2637	22	12	a	a	DET
dti-2637	22	13	long	long	ADJ
dti-2637	22	14	-	-	PUNCT
dti-2637	22	15	term	term	NOUN
dti-2637	22	16	overall	overall	ADJ
dti-2637	22	17	survival	survival	NOUN
dti-2637	22	18	in	in	ADP
dti-2637	22	19	msi	msi	PROPN
dti-2637	22	20	-	-	ADJ
dti-2637	22	21	high	high	ADJ
dti-2637	22	22	/	/	SYM
dti-2637	22	23	dmmr	dmmr	NOUN
dti-2637	22	24	mcrc	mcrc	NOUN
dti-2637	22	25	(	(	PUNCT
dti-2637	22	26	3	3	NUM
dti-2637	22	27	)	)	PUNCT
dti-2637	22	28	.	.	PUNCT
dti-2637	23	1	recent	recent	ADJ
dti-2637	23	2	clinical	clinical	ADJ
dti-2637	23	3	trials	trial	NOUN
dti-2637	23	4	data	datum	NOUN
dti-2637	23	5	suggest	suggest	VERB
dti-2637	23	6	that	that	SCONJ
dti-2637	23	7	the	the	DET
dti-2637	23	8	combination	combination	NOUN
dti-2637	23	9	of	of	ADP
dti-2637	23	10	nivolumab	nivolumab	NOUN
dti-2637	23	11	with	with	ADP
dti-2637	23	12	multikinase	multikinase	NOUN
dti-2637	23	13	or	or	CCONJ
dti-2637	23	14	histone	histone	NOUN
dti-2637	23	15	deacetylase	deacetylase	NOUN
dti-2637	23	16	inhibitors	inhibitor	NOUN
dti-2637	23	17	demonstrates	demonstrate	VERB
dti-2637	23	18	promising	promise	VERB
dti-2637	23	19	synergistic	synergistic	ADJ
dti-2637	23	20	activity	activity	NOUN
dti-2637	23	21	in	in	ADP
dti-2637	23	22	patients	patient	NOUN
dti-2637	23	23	with	with	ADP
dti-2637	23	24	microsatellite	microsatellite	ADJ
dti-2637	23	25	stability	stability	NOUN
dti-2637	23	26	(	(	PUNCT
dti-2637	23	27	mss)/mismatch	mss)/mismatch	NOUN
dti-2637	23	28	repair	repair	NOUN
dti-2637	23	29	proficient	proficient	ADJ
dti-2637	23	30	(	(	PUNCT
dti-2637	23	31	pmmr	pmmr	NOUN
dti-2637	23	32	)	)	PUNCT
dti-2637	23	33	mcrc	mcrc	NOUN
dti-2637	23	34	,	,	PUNCT
dti-2637	23	35	which	which	PRON
dti-2637	23	36	is	be	AUX
dti-2637	23	37	detected	detect	VERB
dti-2637	23	38	in	in	ADP
dti-2637	23	39	approximately	approximately	ADV
dti-2637	23	40	95	95	NUM
dti-2637	23	41	%	%	NOUN
dti-2637	23	42	of	of	ADP
dti-2637	23	43	all	all	DET
dti-2637	23	44	mcrc	mcrc	NOUN
dti-2637	23	45	cases	case	NOUN
dti-2637	23	46	(	(	PUNCT
dti-2637	23	47	4,5	4,5	NUM
dti-2637	23	48	)	)	PUNCT
dti-2637	23	49	.	.	PUNCT
dti-2637	24	1	however	however	ADV
dti-2637	24	2	,	,	PUNCT
dti-2637	24	3	the	the	DET
dti-2637	24	4	molecular	molecular	ADJ
dti-2637	24	5	features	feature	NOUN
dti-2637	24	6	of	of	ADP
dti-2637	24	7	mss	mss	PROPN
dti-2637	24	8	/	/	SYM
dti-2637	24	9	pmmr	pmmr	NOUN
dti-2637	24	10	that	that	PRON
dti-2637	24	11	lead	lead	VERB
dti-2637	24	12	to	to	ADP
dti-2637	24	13	enhanced	enhanced	ADJ
dti-2637	24	14	tumor	tumor	NOUN
dti-2637	24	15	immunogenicity	immunogenicity	NOUN
dti-2637	24	16	and	and	CCONJ
dti-2637	24	17	sensitivity	sensitivity	NOUN
dti-2637	24	18	to	to	ADP
dti-2637	24	19	immune	immune	ADJ
dti-2637	24	20	checkpoint	checkpoint	NOUN
dti-2637	24	21	inhibitors	inhibitor	NOUN
dti-2637	24	22	are	be	AUX
dti-2637	24	23	to	to	PART
dti-2637	24	24	be	be	AUX
dti-2637	24	25	discussed	discuss	VERB
dti-2637	24	26	.	.	PUNCT
dti-2637	25	1	the	the	DET
dti-2637	25	2	use	use	NOUN
dti-2637	25	3	of	of	ADP
dti-2637	25	4	immune	immune	ADJ
dti-2637	25	5	checkpoint	checkpoint	NOUN
dti-2637	25	6	inhibitors	inhibitor	NOUN
dti-2637	25	7	,	,	PUNCT
dti-2637	25	8	including	include	VERB
dti-2637	25	9	nivolumab	nivolumab	NOUN
dti-2637	25	10	,	,	PUNCT
dti-2637	25	11	has	have	AUX
dti-2637	25	12	introduced	introduce	VERB
dti-2637	25	13	new	new	ADJ
dti-2637	25	14	atypical	atypical	ADJ
dti-2637	25	15	response	response	NOUN
dti-2637	25	16	patterns	pattern	NOUN
dti-2637	25	17	,	,	PUNCT
dti-2637	25	18	such	such	ADJ
dti-2637	25	19	as	as	ADP
dti-2637	25	20	dissociated	dissociated	ADJ
dti-2637	25	21	response	response	NOUN
dti-2637	25	22	.	.	PUNCT
dti-2637	26	1	the	the	DET
dti-2637	26	2	most	most	ADV
dti-2637	26	3	common	common	ADJ
dti-2637	26	4	definition	definition	NOUN
dti-2637	26	5	of	of	ADP
dti-2637	26	6	a	a	DET
dti-2637	26	7	dissociated	dissociate	VERB
dti-2637	26	8	response	response	NOUN
dti-2637	26	9	is	be	AUX
dti-2637	26	10	the	the	DET
dti-2637	26	11	coexistence	coexistence	NOUN
dti-2637	26	12	of	of	ADP
dti-2637	26	13	both	both	DET
dti-2637	26	14	responding	respond	VERB
dti-2637	26	15	and	and	CCONJ
dti-2637	26	16	non	non	ADJ
dti-2637	26	17	-	-	ADJ
dti-2637	26	18	responding	respond	VERB
dti-2637	26	19	lesions	lesion	NOUN
dti-2637	26	20	within	within	ADP
dti-2637	26	21	the	the	DET
dti-2637	26	22	same	same	ADJ
dti-2637	26	23	patient	patient	NOUN
dti-2637	26	24	(	(	PUNCT
dti-2637	26	25	6	6	NUM
dti-2637	26	26	)	)	PUNCT
dti-2637	26	27	.	.	PUNCT
dti-2637	27	1	however	however	ADV
dti-2637	27	2	,	,	PUNCT
dti-2637	27	3	there	there	PRON
dti-2637	27	4	is	be	VERB
dti-2637	27	5	no	no	DET
dti-2637	27	6	established	establish	VERB
dti-2637	27	7	terminology	terminology	NOUN
dti-2637	27	8	as	as	ADV
dti-2637	27	9	well	well	ADV
dti-2637	27	10	as	as	ADP
dti-2637	27	11	standard	standard	ADJ
dti-2637	27	12	criteria	criterion	NOUN
dti-2637	27	13	of	of	ADP
dti-2637	27	14	definition	definition	NOUN
dti-2637	27	15	for	for	ADP
dti-2637	27	16	dissociated	dissociated	ADJ
dti-2637	27	17	response	response	NOUN
dti-2637	27	18	;	;	PUNCT
dti-2637	27	19	different	different	ADJ
dti-2637	27	20	terms	term	NOUN
dti-2637	27	21	such	such	ADJ
dti-2637	27	22	as	as	ADP
dti-2637	27	23	mixed	mixed	ADJ
dti-2637	27	24	or	or	CCONJ
dti-2637	27	25	heterogeneous	heterogeneous	ADJ
dti-2637	27	26	response	response	NOUN
dti-2637	27	27	are	be	AUX
dti-2637	27	28	used	use	VERB
dti-2637	27	29	.	.	PUNCT
dti-2637	28	1	although	although	SCONJ
dti-2637	28	2	various	various	ADJ
dti-2637	28	3	types	type	NOUN
dti-2637	28	4	of	of	ADP
dti-2637	28	5	dissociated	dissociate	VERB
dti-2637	28	6	response	response	NOUN
dti-2637	28	7	to	to	ADP
dti-2637	28	8	nivolumab	nivolumab	NOUN
dti-2637	28	9	have	have	AUX
dti-2637	28	10	been	be	AUX
dti-2637	28	11	described	describe	VERB
dti-2637	28	12	in	in	ADP
dti-2637	28	13	many	many	ADJ
dti-2637	28	14	solid	solid	ADJ
dti-2637	28	15	tumors	tumor	NOUN
dti-2637	28	16	(	(	PUNCT
dti-2637	28	17	7	7	NUM
dti-2637	28	18	-	-	SYM
dti-2637	28	19	9	9	NUM
dti-2637	28	20	)	)	PUNCT
dti-2637	28	21	,	,	PUNCT
dti-2637	28	22	there	there	PRON
dti-2637	28	23	are	be	VERB
dti-2637	28	24	no	no	DET
dti-2637	28	25	data	datum	NOUN
dti-2637	28	26	regarding	regard	VERB
dti-2637	28	27	such	such	ADJ
dti-2637	28	28	response	response	NOUN
dti-2637	28	29	in	in	ADP
dti-2637	28	30	mcrc	mcrc	NOUN
dti-2637	28	31	patients	patient	NOUN
dti-2637	28	32	with	with	ADP
dti-2637	28	33	mss/	mss/	NOUN
dti-2637	28	34	pmmr	pmmr	ADJ
dti-2637	28	35	phenotype	phenotype	NOUN
dti-2637	28	36	.	.	PUNCT
dti-2637	29	1	here	here	ADV
dti-2637	29	2	we	we	PRON
dti-2637	29	3	report	report	VERB
dti-2637	29	4	a	a	DET
dti-2637	29	5	case	case	NOUN
dti-2637	29	6	diagnosed	diagnose	VERB
dti-2637	29	7	with	with	ADP
dti-2637	29	8	mss	mss	PROPN
dti-2637	29	9	/	/	SYM
dti-2637	29	10	pmmr	pmmr	PROPN
dti-2637	29	11	mcrc	mcrc	NOUN
dti-2637	29	12	who	who	PRON
dti-2637	29	13	has	have	AUX
dti-2637	29	14	achieved	achieve	VERB
dti-2637	29	15	a	a	DET
dti-2637	29	16	durable	durable	ADJ
dti-2637	29	17	response	response	NOUN
dti-2637	29	18	to	to	ADP
dti-2637	29	19	nivolumab	nivolumab	NOUN
dti-2637	29	20	with	with	ADP
dti-2637	29	21	atypical	atypical	ADJ
dti-2637	29	22	reaction	reaction	NOUN
dti-2637	29	23	after	after	ADP
dti-2637	29	24	progression	progression	NOUN
dti-2637	29	25	following	follow	VERB
dti-2637	29	26	firstand	firstand	ADJ
dti-2637	29	27	second	second	ADJ
dti-2637	29	28	line	line	NOUN
dti-2637	29	29	chemotherapy	chemotherapy	NOUN
dti-2637	29	30	with	with	ADP
dti-2637	29	31	antiangiogenic	antiangiogenic	ADJ
dti-2637	29	32	therapy	therapy	NOUN
dti-2637	29	33	.	.	PUNCT
dti-2637	30	1	case	case	NOUN
dti-2637	30	2	report	report	VERB
dti-2637	30	3	patient	patient	ADJ
dti-2637	30	4	information	information	NOUN
dti-2637	30	5	a	a	DET
dti-2637	30	6	42	42	NUM
dti-2637	30	7	-	-	PUNCT
dti-2637	30	8	year	year	NOUN
dti-2637	30	9	-	-	PUNCT
dti-2637	30	10	old	old	ADJ
dti-2637	30	11	man	man	NOUN
dti-2637	30	12	,	,	PUNCT
dti-2637	30	13	never	never	ADV
dti-2637	30	14	smoker	smoker	ADJ
dti-2637	30	15	,	,	PUNCT
dti-2637	30	16	with	with	ADP
dti-2637	30	17	abdominal	abdominal	ADJ
dti-2637	30	18	pain	pain	NOUN
dti-2637	30	19	accompanied	accompany	VERB
dti-2637	30	20	by	by	ADP
dti-2637	30	21	nausea	nausea	NOUN
dti-2637	30	22	was	be	AUX
dti-2637	30	23	taken	take	VERB
dti-2637	30	24	by	by	ADP
dti-2637	30	25	ambulance	ambulance	NOUN
dti-2637	30	26	to	to	ADP
dti-2637	30	27	the	the	DET
dti-2637	30	28	local	local	ADJ
dti-2637	30	29	hospital	hospital	NOUN
dti-2637	30	30	in	in	ADP
dti-2637	30	31	august	august	PROPN
dti-2637	30	32	2017	2017	NUM
dti-2637	30	33	,	,	PUNCT
dti-2637	30	34	where	where	SCONJ
dti-2637	30	35	intestinal	intestinal	ADJ
dti-2637	30	36	obstruction	obstruction	NOUN
dti-2637	30	37	was	be	AUX
dti-2637	30	38	verified	verify	VERB
dti-2637	30	39	.	.	PUNCT
dti-2637	31	1	his	his	PRON
dti-2637	31	2	medical	medical	ADJ
dti-2637	31	3	history	history	NOUN
dti-2637	31	4	included	include	VERB
dti-2637	31	5	сhronic	сhronic	ADJ
dti-2637	31	6	cholecystitis	cholecystitis	NOUN
dti-2637	31	7	,	,	PUNCT
dti-2637	31	8	chronic	chronic	ADJ
dti-2637	31	9	pancreatitis	pancreatitis	NOUN
dti-2637	31	10	,	,	PUNCT
dti-2637	31	11	and	and	CCONJ
dti-2637	31	12	mixed	mixed	ADJ
dti-2637	31	13	etiology	etiology	NOUN
dti-2637	31	14	of	of	ADP
dti-2637	31	15	hepatitis	hepatitis	NOUN
dti-2637	31	16	.	.	PUNCT
dti-2637	32	1	the	the	DET
dti-2637	32	2	patient	patient	ADJ
dti-2637	32	3	underwent	underwent	NOUN
dti-2637	32	4	abdominal	abdominal	ADJ
dti-2637	32	5	stoma	stoma	NOUN
dti-2637	32	6	surgery	surgery	NOUN
dti-2637	32	7	.	.	PUNCT
dti-2637	33	1	biopsy	biopsy	NOUN
dti-2637	33	2	revealed	reveal	VERB
dti-2637	33	3	a	a	DET
dti-2637	33	4	highly	highly	ADV
dti-2637	33	5	differentiated	differentiate	VERB
dti-2637	33	6	adenocarcinoma	adenocarcinoma	NOUN
dti-2637	33	7	.	.	PUNCT
dti-2637	34	1	the	the	DET
dti-2637	34	2	patient	patient	NOUN
dti-2637	34	3	independently	independently	ADV
dti-2637	34	4	visited	visit	VERB
dti-2637	34	5	tomsk	tomsk	PROPN
dti-2637	34	6	cancer	cancer	PROPN
dti-2637	34	7	research	research	PROPN
dti-2637	34	8	institute	institute	PROPN
dti-2637	34	9	for	for	ADP
dti-2637	34	10	further	further	ADJ
dti-2637	34	11	examination	examination	NOUN
dti-2637	34	12	,	,	PUNCT
dti-2637	34	13	where	where	SCONJ
dti-2637	34	14	he	he	PRON
dti-2637	34	15	underwent	undergo	VERB
dti-2637	34	16	left	leave	VERB
dti-2637	34	17	hemicolectomy	hemicolectomy	NOUN
dti-2637	34	18	and	and	CCONJ
dti-2637	34	19	colostomy	colostomy	VERB
dti-2637	34	20	suturing	suture	VERB
dti-2637	34	21	.	.	PUNCT
dti-2637	35	1	pathologic	pathologic	ADJ
dti-2637	35	2	verification	verification	NOUN
dti-2637	35	3	of	of	ADP
dti-2637	35	4	resection	resection	NOUN
dti-2637	35	5	specimens	specimen	NOUN
dti-2637	35	6	confirmed	confirm	VERB
dti-2637	35	7	moderately	moderately	ADV
dti-2637	35	8	differentiated	differentiate	VERB
dti-2637	35	9	adenocarcinoma	adenocarcinoma	NOUN
dti-2637	35	10	with	with	ADP
dti-2637	35	11	mucinous	mucinous	ADJ
dti-2637	35	12	features	feature	NOUN
dti-2637	35	13	and	and	CCONJ
dti-2637	35	14	foci	focus	NOUN
dti-2637	35	15	of	of	ADP
dti-2637	35	16	severe	severe	ADJ
dti-2637	35	17	fibrosis	fibrosis	NOUN
dti-2637	35	18	,	,	PUNCT
dti-2637	35	19	as	as	ADV
dti-2637	35	20	well	well	ADV
dti-2637	35	21	as	as	ADP
dti-2637	35	22	comedo	comedo	NOUN
dti-2637	35	23	necrosis	necrosis	NOUN
dti-2637	35	24	and	and	CCONJ
dti-2637	35	25	with	with	ADP
dti-2637	35	26	an	an	DET
dti-2637	35	27	accompanying	accompanying	ADJ
dti-2637	35	28	lymphocytic	lymphocytic	ADJ
dti-2637	35	29	infiltrate	infiltrate	NOUN
dti-2637	35	30	and	and	CCONJ
dti-2637	35	31	invasion	invasion	NOUN
dti-2637	35	32	into	into	ADP
dti-2637	35	33	the	the	DET
dti-2637	35	34	serous	serous	ADJ
dti-2637	35	35	membrane	membrane	NOUN
dti-2637	35	36	.	.	PUNCT
dti-2637	36	1	the	the	DET
dti-2637	36	2	patient	patient	NOUN
dti-2637	36	3	was	be	AUX
dti-2637	36	4	diagnosed	diagnose	VERB
dti-2637	36	5	with	with	ADP
dti-2637	36	6	splenic	splenic	ADJ
dti-2637	36	7	flexure	flexure	NOUN
dti-2637	36	8	colon	colon	NOUN
dti-2637	36	9	cancer	cancer	NOUN
dti-2637	36	10	,	,	PUNCT
dti-2637	36	11	t4n3m0	t4n3m0	NOUN
dti-2637	36	12	,	,	PUNCT
dti-2637	36	13	stage	stage	NOUN
dti-2637	36	14	iiic	iiic	PROPN
dti-2637	36	15	.	.	PUNCT
dti-2637	37	1	however	however	ADV
dti-2637	37	2	,	,	PUNCT
dti-2637	37	3	a	a	DET
dti-2637	37	4	month	month	NOUN
dti-2637	37	5	later	later	ADV
dti-2637	37	6	,	,	PUNCT
dti-2637	37	7	during	during	ADP
dti-2637	37	8	an	an	DET
dti-2637	37	9	additional	additional	ADJ
dti-2637	37	10	examination	examination	NOUN
dti-2637	37	11	in	in	ADP
dti-2637	37	12	october	october	PROPN
dti-2637	37	13	2017	2017	NUM
dti-2637	37	14	,	,	PUNCT
dti-2637	37	15	supraclavicular	supraclavicular	ADJ
dti-2637	37	16	lymph	lymph	NOUN
dti-2637	37	17	node	node	NOUN
dti-2637	37	18	metastases	metastasis	NOUN
dti-2637	37	19	on	on	ADP
dti-2637	37	20	both	both	DET
dti-2637	37	21	sides	side	NOUN
dti-2637	37	22	were	be	AUX
dti-2637	37	23	detected	detect	VERB
dti-2637	37	24	.	.	PUNCT
dti-2637	38	1	due	due	ADP
dti-2637	38	2	to	to	ADP
dti-2637	38	3	definitive	definitive	ADJ
dti-2637	38	4	evidence	evidence	NOUN
dti-2637	38	5	of	of	ADP
dti-2637	38	6	disseminated	disseminate	VERB
dti-2637	38	7	disease	disease	NOUN
dti-2637	38	8	,	,	PUNCT
dti-2637	38	9	the	the	DET
dti-2637	38	10	patient	patient	NOUN
dti-2637	38	11	was	be	AUX
dti-2637	38	12	upstaged	upstaged	ADJ
dti-2637	38	13	to	to	PART
dti-2637	38	14	stage	stage	VERB
dti-2637	38	15	iv	iv	NUM
dti-2637	38	16	.	.	PUNCT
dti-2637	39	1	molecular	molecular	ADJ
dti-2637	39	2	testing	testing	NOUN
dti-2637	39	3	of	of	ADP
dti-2637	39	4	the	the	DET
dti-2637	39	5	tumor	tumor	NOUN
dti-2637	39	6	revealed	reveal	VERB
dti-2637	39	7	the	the	DET
dti-2637	39	8	krasp.g12d	krasp.g12d	PROPN
dti-2637	39	9	mutation	mutation	NOUN
dti-2637	39	10	.	.	PUNCT
dti-2637	40	1	mss	mss	PROPN
dti-2637	40	2	/	/	SYM
dti-2637	40	3	pmmr	pmmr	ADJ
dti-2637	40	4	phenotype	phenotype	NOUN
dti-2637	40	5	immunohistochemistry	immunohistochemistry	NOUN
dti-2637	40	6	analysis	analysis	NOUN
dti-2637	40	7	of	of	ADP
dti-2637	40	8	mmr	mmr	NOUN
dti-2637	40	9	protein	protein	NOUN
dti-2637	40	10	expression	expression	NOUN
dti-2637	40	11	(	(	PUNCT
dti-2637	40	12	mlh1	mlh1	PROPN
dti-2637	40	13	,	,	PUNCT
dti-2637	40	14	msh2	msh2	NOUN
dti-2637	40	15	,	,	PUNCT
dti-2637	40	16	msh6	msh6	NOUN
dti-2637	40	17	,	,	PUNCT
dti-2637	40	18	and	and	CCONJ
dti-2637	40	19	pms2	pms2	PROPN
dti-2637	40	20	)	)	PUNCT
dti-2637	40	21	demonstrated	demonstrate	VERB
dti-2637	40	22	a	a	DET
dti-2637	40	23	homogeneous	homogeneous	ADJ
dti-2637	40	24	pattern	pattern	NOUN
dti-2637	40	25	of	of	ADP
dti-2637	40	26	their	their	PRON
dti-2637	40	27	proficiency	proficiency	NOUN
dti-2637	40	28	in	in	ADP
dti-2637	40	29	colon	colon	NOUN
dti-2637	40	30	tumor	tumor	NOUN
dti-2637	40	31	tissue	tissue	NOUN
dti-2637	40	32	(	(	PUNCT
dti-2637	40	33	fig	fig	NOUN
dti-2637	40	34	.	.	PUNCT
dti-2637	41	1	1a	1a	NOUN
dti-2637	41	2	)	)	PUNCT
dti-2637	41	3	.	.	PUNCT
dti-2637	42	1	polymerase	polymerase	NOUN
dti-2637	42	2	chain	chain	NOUN
dti-2637	42	3	reaction	reaction	NOUN
dti-2637	42	4	(	(	PUNCT
dti-2637	42	5	pcr	pcr	PROPN
dti-2637	42	6	)	)	PUNCT
dti-2637	42	7	assay	assay	PROPN
dti-2637	42	8	confirmed	confirm	VERB
dti-2637	42	9	the	the	DET
dti-2637	42	10	mss	mss	PROPN
dti-2637	42	11	phenotype	phenotype	NOUN
dti-2637	42	12	for	for	ADP
dti-2637	42	13	three	three	NUM
dti-2637	42	14	different	different	ADJ
dti-2637	42	15	colon	colon	NOUN
dti-2637	42	16	tumor	tumor	NOUN
dti-2637	42	17	specimens	specimen	NOUN
dti-2637	42	18	(	(	PUNCT
dti-2637	42	19	fig	fig	NOUN
dti-2637	42	20	.	.	PUNCT
dti-2637	42	21	1b	1b	NUM
dti-2637	42	22	)	)	PUNCT
dti-2637	42	23	.	.	PUNCT
dti-2637	43	1	with	with	ADP
dti-2637	43	2	respect	respect	NOUN
dti-2637	43	3	to	to	ADP
dti-2637	43	4	pd	pd	PROPN
dti-2637	43	5	-	-	PUNCT
dti-2637	43	6	l1	l1	PROPN
dti-2637	43	7	status	status	NOUN
dti-2637	43	8	,	,	PUNCT
dti-2637	43	9	a	a	DET
dti-2637	43	10	weak	weak	ADJ
dti-2637	43	11	expression	expression	NOUN
dti-2637	43	12	(	(	PUNCT
dti-2637	43	13	tps-1	tps-1	NOUN
dti-2637	43	14	%	%	NOUN
dti-2637	43	15	and	and	CCONJ
dti-2637	43	16	cps-6.0	cps-6.0	NOUN
dti-2637	43	17	)	)	PUNCT
dti-2637	43	18	in	in	ADP
dti-2637	43	19	several	several	ADJ
dti-2637	43	20	colon	colon	NOUN
dti-2637	43	21	tumor	tumor	NOUN
dti-2637	43	22	specimens	specimen	NOUN
dti-2637	43	23	was	be	AUX
dti-2637	43	24	independently	independently	ADV
dti-2637	43	25	detected	detect	VERB
dti-2637	43	26	by	by	ADP
dti-2637	43	27	two	two	NUM
dti-2637	43	28	researchers	researcher	NOUN
dti-2637	43	29	.	.	PUNCT
dti-2637	44	1	chemotherapeutic	chemotherapeutic	ADJ
dti-2637	44	2	intervention	intervention	NOUN
dti-2637	44	3	patient	patient	NOUN
dti-2637	44	4	was	be	AUX
dti-2637	44	5	started	start	VERB
dti-2637	44	6	on	on	ADP
dti-2637	44	7	a	a	DET
dti-2637	44	8	first	first	ADJ
dti-2637	44	9	-	-	PUNCT
dti-2637	44	10	line	line	NOUN
dti-2637	44	11	folfox	folfox	VERB
dti-2637	44	12	plus	plus	CCONJ
dti-2637	44	13	bevacizumab	bevacizumab	NOUN
dti-2637	44	14	regimen	regiman	NOUN
dti-2637	44	15	,	,	PUNCT
dti-2637	44	16	which	which	PRON
dti-2637	44	17	consisted	consist	VERB
dti-2637	44	18	of	of	ADP
dti-2637	44	19	bevacizumab	bevacizumab	NOUN
dti-2637	44	20	5	5	NUM
dti-2637	44	21	mg	mg	PROPN
dti-2637	44	22	/	/	SYM
dti-2637	44	23	kg	kg	NOUN
dti-2637	44	24	on	on	ADP
dti-2637	44	25	day	day	NOUN
dti-2637	44	26	1	1	NUM
dti-2637	44	27	,	,	PUNCT
dti-2637	44	28	oxaliplatin	oxaliplatin	NOUN
dti-2637	44	29	85	85	NUM
dti-2637	44	30	mg	mg	NUM
dti-2637	44	31	/	/	SYM
dti-2637	44	32	m2	m2	PROPN
dti-2637	44	33	on	on	ADP
dti-2637	44	34	day	day	NOUN
dti-2637	44	35	1	1	NUM
dti-2637	44	36	,	,	PUNCT
dti-2637	44	37	leucovorin	leucovorin	NOUN
dti-2637	44	38	400	400	NUM
dti-2637	44	39	mg	mg	PROPN
dti-2637	44	40	/	/	SYM
dti-2637	44	41	m2	m2	PROPN
dti-2637	44	42	on	on	ADP
dti-2637	44	43	day	day	NOUN
dti-2637	44	44	1	1	NUM
dti-2637	44	45	,	,	PUNCT
dti-2637	44	46	and	and	CCONJ
dti-2637	44	47	5	5	NUM
dti-2637	44	48	-	-	PUNCT
dti-2637	44	49	fluorouracil	fluorouracil	NOUN
dti-2637	44	50	400	400	NUM
dti-2637	44	51	mg	mg	NUM
dti-2637	44	52	/	/	SYM
dti-2637	44	53	m2	m2	PROPN
dti-2637	44	54	bolus	bolus	ADJ
dti-2637	44	55	injection	injection	NOUN
dti-2637	44	56	followed	follow	VERB
dti-2637	44	57	by	by	ADP
dti-2637	44	58	46	46	NUM
dti-2637	44	59	-	-	PUNCT
dti-2637	44	60	hour	hour	NOUN
dti-2637	44	61	continuous	continuous	ADJ
dti-2637	44	62	infusion	infusion	NOUN
dti-2637	44	63	of	of	ADP
dti-2637	44	64	5	5	NUM
dti-2637	44	65	-	-	PUNCT
dti-2637	44	66	fluorouracil	fluorouracil	NOUN
dti-2637	44	67	2,400	2,400	NUM
dti-2637	44	68	mg	mg	PROPN
dti-2637	44	69	/	/	SYM
dti-2637	44	70	m2	m2	PROPN
dti-2637	44	71	on	on	ADP
dti-2637	44	72	day	day	NOUN
dti-2637	44	73	1	1	NUM
dti-2637	44	74	.	.	PUNCT
dti-2637	45	1	after	after	ADP
dti-2637	45	2	four	four	NUM
dti-2637	45	3	cycles	cycle	NOUN
dti-2637	45	4	of	of	ADP
dti-2637	45	5	treatment	treatment	NOUN
dti-2637	45	6	,	,	PUNCT
dti-2637	45	7	the	the	DET
dti-2637	45	8	partial	partial	ADJ
dti-2637	45	9	response	response	NOUN
dti-2637	45	10	per	per	ADP
dti-2637	45	11	recist	recist	NOUN
dti-2637	45	12	1.1	1.1	NUM
dti-2637	45	13	was	be	AUX
dti-2637	45	14	recorded	record	VERB
dti-2637	45	15	.	.	PUNCT
dti-2637	46	1	in	in	ADP
dti-2637	46	2	june	june	PROPN
dti-2637	46	3	2018	2018	NUM
dti-2637	46	4	,	,	PUNCT
dti-2637	46	5	the	the	DET
dti-2637	46	6	patient	patient	NOUN
dti-2637	46	7	completed	complete	VERB
dti-2637	46	8	14	14	NUM
dti-2637	46	9	cycles	cycle	NOUN
dti-2637	46	10	of	of	ADP
dti-2637	46	11	chemotherapy	chemotherapy	NOUN
dti-2637	46	12	and	and	CCONJ
dti-2637	46	13	following	follow	VERB
dti-2637	46	14	the	the	DET
dti-2637	46	15	chest	chest	NOUN
dti-2637	46	16	computed	compute	VERB
dti-2637	46	17	tomography	tomography	NOUN
dti-2637	46	18	(	(	PUNCT
dti-2637	46	19	ct	ct	NOUN
dti-2637	46	20	)	)	PUNCT
dti-2637	46	21	images	image	NOUN
dti-2637	46	22	showed	show	VERB
dti-2637	46	23	the	the	DET
dti-2637	46	24	appearance	appearance	NOUN
dti-2637	46	25	of	of	ADP
dti-2637	46	26	randomly	randomly	ADV
dti-2637	46	27	located	locate	VERB
dti-2637	46	28	focal	focal	ADJ
dti-2637	46	29	nodules	nodule	NOUN
dti-2637	46	30	of	of	ADP
dti-2637	46	31	up	up	ADP
dti-2637	46	32	to	to	PART
dti-2637	46	33	7	7	NUM
dti-2637	46	34	mm	mm	NOUN
dti-2637	46	35	in	in	ADP
dti-2637	46	36	size	size	NOUN
dti-2637	46	37	consistent	consistent	ADJ
dti-2637	46	38	with	with	ADP
dti-2637	46	39	lung	lung	NOUN
dti-2637	46	40	metastases	metastasis	NOUN
dti-2637	46	41	.	.	PUNCT
dti-2637	47	1	the	the	DET
dti-2637	47	2	levels	level	NOUN
dti-2637	47	3	of	of	ADP
dti-2637	47	4	tumor	tumor	NOUN
dti-2637	47	5	markers	marker	NOUN
dti-2637	47	6	such	such	ADJ
dti-2637	47	7	as	as	ADP
dti-2637	47	8	cea	cea	PROPN
dti-2637	47	9	,	,	PUNCT
dti-2637	47	10	ca19	ca19	PROPN
dti-2637	47	11	-	-	PUNCT
dti-2637	47	12	9	9	NUM
dti-2637	47	13	,	,	PUNCT
dti-2637	47	14	and	and	CCONJ
dti-2637	47	15	ca242	ca242	NOUN
dti-2637	47	16	did	do	AUX
dti-2637	47	17	not	not	PART
dti-2637	47	18	exceed	exceed	VERB
dti-2637	47	19	the	the	DET
dti-2637	47	20	fig	fig	NOUN
dti-2637	47	21	.	.	PUNCT
dti-2637	48	1	1	1	NUM
dti-2637	48	2	immunohistochemical	immunohistochemical	ADJ
dti-2637	48	3	staining	staining	NOUN
dti-2637	48	4	of	of	ADP
dti-2637	48	5	mmr	mmr	PROPN
dti-2637	48	6	proteins	protein	NOUN
dti-2637	48	7	.	.	PUNCT
dti-2637	49	1	positive	positive	ADJ
dti-2637	49	2	expression	expression	NOUN
dti-2637	49	3	of	of	ADP
dti-2637	49	4	mlh1	mlh1	PROPN
dti-2637	49	5	,	,	PUNCT
dti-2637	49	6	msh2	msh2	NOUN
dti-2637	49	7	,	,	PUNCT
dti-2637	49	8	msh6	msh6	NOUN
dti-2637	49	9	,	,	PUNCT
dti-2637	49	10	and	and	CCONJ
dti-2637	49	11	pms2	pms2	NOUN
dti-2637	49	12	in	in	ADP
dti-2637	49	13	the	the	DET
dti-2637	49	14	colon	colon	NOUN
dti-2637	49	15	tumor	tumor	NOUN
dti-2637	49	16	tissue	tissue	NOUN
dti-2637	49	17	(	(	PUNCT
dti-2637	49	18	magnification	magnification	NOUN
dti-2637	49	19	×200	×200	PROPN
dti-2637	49	20	)	)	PUNCT
dti-2637	49	21	(	(	PUNCT
dti-2637	49	22	a	a	X
dti-2637	49	23	)	)	PUNCT
dti-2637	49	24	;	;	PUNCT
dti-2637	49	25	msi	msi	PROPN
dti-2637	49	26	test	test	PROPN
dti-2637	49	27	electropherograms	electropherogram	NOUN
dti-2637	49	28	with	with	ADP
dti-2637	49	29	nr-27	nr-27	PRON
dti-2637	49	30	,	,	PUNCT
dti-2637	49	31	nr21	nr21	PROPN
dti-2637	49	32	,	,	PUNCT
dti-2637	49	33	nr-24	nr-24	PRON
dti-2637	49	34	,	,	PUNCT
dti-2637	49	35	bat25	bat25	PROPN
dti-2637	49	36	,	,	PUNCT
dti-2637	49	37	and	and	CCONJ
dti-2637	49	38	bat26	bat26	VERB
dti-2637	49	39	markers	marker	NOUN
dti-2637	49	40	in	in	ADP
dti-2637	49	41	the	the	DET
dti-2637	49	42	colon	colon	NOUN
dti-2637	49	43	tumor	tumor	NOUN
dti-2637	49	44	and	and	CCONJ
dti-2637	49	45	lymph	lymph	NOUN
dti-2637	49	46	node	node	ADJ
dti-2637	49	47	specimens	specimen	NOUN
dti-2637	49	48	(	(	PUNCT
dti-2637	49	49	b	b	NOUN
dti-2637	49	50	)	)	PUNCT
dti-2637	49	51	.	.	PUNCT
dti-2637	50	1	mmr	mmr	PROPN
dti-2637	50	2	=	=	SYM
dti-2637	50	3	mismatch	mismatch	PROPN
dti-2637	50	4	repair	repair	NOUN
dti-2637	50	5	;	;	PUNCT
dti-2637	50	6	msi	msi	NOUN
dti-2637	50	7	=	=	SYM
dti-2637	50	8	microsatellite	microsatellite	NOUN
dti-2637	50	9	instability	instability	NOUN
dti-2637	50	10	.	.	PUNCT
dti-2637	51	1	long	long	ADJ
dti-2637	51	2	-	-	PUNCT
dti-2637	51	3	term	term	NOUN
dti-2637	51	4	response	response	NOUN
dti-2637	51	5	to	to	ADP
dti-2637	51	6	nivolumab	nivolumab	NOUN
dti-2637	51	7	in	in	ADP
dti-2637	51	8	metastatic	metastatic	ADJ
dti-2637	51	9	colorectal	colorectal	ADJ
dti-2637	51	10	cancer6	cancer6	NOUN
dti-2637	52	1	©	©	ADP
dti-2637	52	2	2024	2024	NUM
dti-2637	53	1	the	the	DET
dti-2637	53	2	authors	author	NOUN
dti-2637	53	3	.	.	PUNCT
dti-2637	54	1	drug	drug	NOUN
dti-2637	54	2	target	target	NOUN
dti-2637	54	3	insights	insight	NOUN
dti-2637	54	4	issn	issn	VERB
dti-2637	54	5	1177	1177	NUM
dti-2637	54	6	-	-	SYM
dti-2637	54	7	3928	3928	NUM
dti-2637	54	8	www.aboutscience.eu/dti	www.aboutscience.eu/dti	VERB
dti-2637	54	9	normal	normal	ADJ
dti-2637	54	10	values	value	NOUN
dti-2637	54	11	,	,	PUNCT
dti-2637	54	12	being	be	AUX
dti-2637	54	13	0	0	NUM
dti-2637	54	14	-	-	SYM
dti-2637	54	15	3.40	3.40	NUM
dti-2637	54	16	ng	ng	PROPN
dti-2637	54	17	/	/	SYM
dti-2637	54	18	ml	ml	PROPN
dti-2637	54	19	for	for	ADP
dti-2637	54	20	cea	cea	PROPN
dti-2637	54	21	,	,	PUNCT
dti-2637	54	22	0	0	NUM
dti-2637	54	23	-	-	SYM
dti-2637	54	24	34	34	NUM
dti-2637	54	25	u	u	NOUN
dti-2637	54	26	/	/	SYM
dti-2637	54	27	ml	ml	X
dti-2637	54	28	for	for	ADP
dti-2637	54	29	ca19	ca19	PROPN
dti-2637	54	30	-	-	PUNCT
dti-2637	54	31	9	9	NUM
dti-2637	54	32	,	,	PUNCT
dti-2637	54	33	and	and	CCONJ
dti-2637	54	34	0	0	NUM
dti-2637	54	35	-	-	SYM
dti-2637	54	36	20.0	20.0	NUM
dti-2637	54	37	u	u	NOUN
dti-2637	54	38	/	/	SYM
dti-2637	54	39	ml	ml	X
dti-2637	54	40	for	for	ADP
dti-2637	54	41	ca242	ca242	PROPN
dti-2637	54	42	.	.	PUNCT
dti-2637	55	1	second	second	ADJ
dti-2637	55	2	-	-	PUNCT
dti-2637	55	3	line	line	NOUN
dti-2637	55	4	treatment	treatment	NOUN
dti-2637	55	5	with	with	ADP
dti-2637	55	6	folfiri	folfiri	NOUN
dti-2637	55	7	and	and	CCONJ
dti-2637	55	8	aflibercept	aflibercept	NOUN
dti-2637	55	9	(	(	PUNCT
dti-2637	55	10	aflibercept	aflibercept	DET
dti-2637	55	11	4	4	NUM
dti-2637	55	12	 	 	SPACE
dti-2637	55	13	mg	mg	PROPN
dti-2637	55	14	/	/	SYM
dti-2637	55	15	kg	kg	PROPN
dti-2637	55	16	on	on	ADP
dti-2637	55	17	day	day	NOUN
dti-2637	55	18	1	1	NUM
dti-2637	55	19	,	,	PUNCT
dti-2637	55	20	irinotecan	irinotecan	NOUN
dti-2637	55	21	180	180	NUM
dti-2637	55	22	 	 	SPACE
dti-2637	55	23	mg	mg	PROPN
dti-2637	55	24	/	/	SYM
dti-2637	55	25	m2	m2	PROPN
dti-2637	55	26	on	on	ADP
dti-2637	55	27	day	day	NOUN
dti-2637	55	28	1	1	NUM
dti-2637	55	29	,	,	PUNCT
dti-2637	55	30	leucovorin	leucovorin	NOUN
dti-2637	55	31	400	400	NUM
dti-2637	55	32	mg	mg	PROPN
dti-2637	55	33	/	/	SYM
dti-2637	55	34	m2	m2	PROPN
dti-2637	55	35	on	on	ADP
dti-2637	55	36	day	day	NOUN
dti-2637	55	37	1	1	NUM
dti-2637	55	38	,	,	PUNCT
dti-2637	55	39	5	5	NUM
dti-2637	55	40	-	-	PUNCT
dti-2637	55	41	fluorouracil	fluorouracil	NOUN
dti-2637	55	42	400	400	NUM
dti-2637	55	43	mg	mg	NUM
dti-2637	55	44	/	/	SYM
dti-2637	55	45	m2	m2	PROPN
dti-2637	55	46	bolus	bolus	ADJ
dti-2637	55	47	injection	injection	NOUN
dti-2637	55	48	followed	follow	VERB
dti-2637	55	49	by	by	ADP
dti-2637	55	50	46	46	NUM
dti-2637	55	51	-	-	PUNCT
dti-2637	55	52	hour	hour	NOUN
dti-2637	55	53	continuous	continuous	ADJ
dti-2637	55	54	infusion	infusion	NOUN
dti-2637	55	55	of	of	ADP
dti-2637	55	56	5	5	NUM
dti-2637	55	57	-	-	PUNCT
dti-2637	55	58	fluorouracil	fluorouracil	NOUN
dti-2637	55	59	2,400	2,400	NUM
dti-2637	55	60	mg	mg	PROPN
dti-2637	55	61	/	/	SYM
dti-2637	55	62	m2	m2	PROPN
dti-2637	55	63	)	)	PUNCT
dti-2637	55	64	was	be	AUX
dti-2637	55	65	initiated	initiate	VERB
dti-2637	55	66	.	.	PUNCT
dti-2637	56	1	repeat	repeat	VERB
dti-2637	56	2	ct	ct	NUM
dti-2637	56	3	images	image	NOUN
dti-2637	56	4	after	after	SCONJ
dti-2637	56	5	three	three	NUM
dti-2637	56	6	cycles	cycle	NOUN
dti-2637	56	7	showed	show	VERB
dti-2637	56	8	no	no	DET
dti-2637	56	9	growth	growth	NOUN
dti-2637	56	10	of	of	ADP
dti-2637	56	11	focal	focal	ADJ
dti-2637	56	12	nodules	nodule	NOUN
dti-2637	56	13	in	in	ADP
dti-2637	56	14	the	the	DET
dti-2637	56	15	lung	lung	NOUN
dti-2637	56	16	.	.	PUNCT
dti-2637	57	1	this	this	DET
dti-2637	57	2	treatment	treatment	NOUN
dti-2637	57	3	was	be	AUX
dti-2637	57	4	associated	associate	VERB
dti-2637	57	5	with	with	ADP
dti-2637	57	6	adverse	adverse	ADJ
dti-2637	57	7	events	event	NOUN
dti-2637	57	8	such	such	ADJ
dti-2637	57	9	as	as	ADP
dti-2637	57	10	of	of	ADP
dti-2637	57	11	grade	grade	NOUN
dti-2637	57	12	2	2	NUM
dti-2637	57	13	hypertension	hypertension	NOUN
dti-2637	57	14	,	,	PUNCT
dti-2637	57	15	nausea	nausea	NOUN
dti-2637	57	16	,	,	PUNCT
dti-2637	57	17	and	and	CCONJ
dti-2637	57	18	thrombocytopenia	thrombocytopenia	PROPN
dti-2637	57	19	.	.	PUNCT
dti-2637	58	1	ct	ct	PROPN
dti-2637	58	2	assessment	assessment	NOUN
dti-2637	58	3	after	after	ADP
dti-2637	58	4	seven	seven	NUM
dti-2637	58	5	cycles	cycle	NOUN
dti-2637	58	6	of	of	ADP
dti-2637	58	7	treatment	treatment	NOUN
dti-2637	58	8	confirmed	confirm	VERB
dti-2637	58	9	a	a	DET
dti-2637	58	10	stable	stable	ADJ
dti-2637	58	11	response	response	NOUN
dti-2637	58	12	.	.	PUNCT
dti-2637	59	1	due	due	ADP
dti-2637	59	2	to	to	ADP
dti-2637	59	3	an	an	DET
dti-2637	59	4	acute	acute	ADJ
dti-2637	59	5	exacerbation	exacerbation	NOUN
dti-2637	59	6	of	of	ADP
dti-2637	59	7	mixed	mixed	ADJ
dti-2637	59	8	etiology	etiology	NOUN
dti-2637	59	9	hepatitis	hepatitis	NOUN
dti-2637	59	10	(	(	PUNCT
dti-2637	59	11	chronic	chronic	ADJ
dti-2637	59	12	hepatitis	hepatitis	PROPN
dti-2637	59	13	b	b	PROPN
dti-2637	59	14	with	with	ADP
dti-2637	59	15	serum	serum	NOUN
dti-2637	59	16	hepatitis	hepatitis	PROPN
dti-2637	59	17	b	b	PROPN
dti-2637	59	18	virus	virus	NOUN
dti-2637	59	19	dna	dna	PROPN
dti-2637	59	20	titer	titer	NOUN
dti-2637	59	21	>	>	NOUN
dti-2637	59	22	105	105	NUM
dti-2637	59	23	copies	copy	NOUN
dti-2637	59	24	/	/	SYM
dti-2637	59	25	ml	ml	NOUN
dti-2637	59	26	and	and	CCONJ
dti-2637	59	27	toxic	toxic	ADJ
dti-2637	59	28	hepatitis	hepatitis	NOUN
dti-2637	59	29	)	)	PUNCT
dti-2637	59	30	and	and	CCONJ
dti-2637	59	31	an	an	DET
dti-2637	59	32	abnormal	abnormal	ADJ
dti-2637	59	33	alanine	alanine	NOUN
dti-2637	59	34	aminotransferase	aminotransferase	NOUN
dti-2637	59	35	exceeding	exceed	VERB
dti-2637	59	36	nine	nine	NUM
dti-2637	59	37	times	time	NOUN
dti-2637	59	38	the	the	DET
dti-2637	59	39	upper	upper	ADJ
dti-2637	59	40	limit	limit	NOUN
dti-2637	59	41	of	of	ADP
dti-2637	59	42	normal	normal	ADJ
dti-2637	59	43	at	at	ADP
dti-2637	59	44	baseline	baseline	NOUN
dti-2637	59	45	,	,	PUNCT
dti-2637	59	46	subsequent	subsequent	ADJ
dti-2637	59	47	treatment	treatment	NOUN
dti-2637	59	48	was	be	AUX
dti-2637	59	49	interrupted	interrupt	VERB
dti-2637	59	50	.	.	PUNCT
dti-2637	60	1	the	the	DET
dti-2637	60	2	patient	patient	NOUN
dti-2637	60	3	received	receive	VERB
dti-2637	60	4	hepatoprotective	hepatoprotective	ADJ
dti-2637	60	5	and	and	CCONJ
dti-2637	60	6	detoxification	detoxification	NOUN
dti-2637	60	7	treatment	treatment	NOUN
dti-2637	60	8	.	.	PUNCT
dti-2637	61	1	approximately	approximately	ADV
dti-2637	61	2	2	2	NUM
dti-2637	61	3	months	month	NOUN
dti-2637	61	4	later	later	ADV
dti-2637	61	5	,	,	PUNCT
dti-2637	61	6	ct	ct	PROPN
dti-2637	61	7	scans	scan	NOUN
dti-2637	61	8	showed	show	VERB
dti-2637	61	9	an	an	DET
dti-2637	61	10	increase	increase	NOUN
dti-2637	61	11	of	of	ADP
dti-2637	61	12	nodule	nodule	ADJ
dti-2637	61	13	size	size	NOUN
dti-2637	61	14	in	in	ADP
dti-2637	61	15	the	the	DET
dti-2637	61	16	lung	lung	NOUN
dti-2637	61	17	(	(	PUNCT
dti-2637	61	18	fig	fig	NOUN
dti-2637	61	19	.	.	PUNCT
dti-2637	61	20	2a	2a	NUM
dti-2637	61	21	)	)	PUNCT
dti-2637	61	22	.	.	PUNCT
dti-2637	62	1	nivolumab	nivolumab	PROPN
dti-2637	62	2	administration	administration	NOUN
dti-2637	62	3	given	give	VERB
dti-2637	62	4	the	the	DET
dti-2637	62	5	fast	fast	ADJ
dti-2637	62	6	progression	progression	NOUN
dti-2637	62	7	and	and	CCONJ
dti-2637	62	8	pd	pd	PROPN
dti-2637	62	9	-	-	PROPN
dti-2637	62	10	l1	l1	PROPN
dti-2637	62	11	status	status	NOUN
dti-2637	62	12	,	,	PUNCT
dti-2637	62	13	treatment	treatment	NOUN
dti-2637	62	14	with	with	ADP
dti-2637	62	15	nivolumab	nivolumab	NOUN
dti-2637	62	16	at	at	ADP
dti-2637	62	17	a	a	DET
dti-2637	62	18	dose	dose	NOUN
dti-2637	62	19	240	240	NUM
dti-2637	62	20	mg	mg	NOUN
dti-2637	62	21	was	be	AUX
dti-2637	62	22	started	start	VERB
dti-2637	62	23	in	in	ADP
dti-2637	62	24	december	december	PROPN
dti-2637	62	25	2018	2018	NUM
dti-2637	62	26	.	.	PUNCT
dti-2637	63	1	three	three	NUM
dti-2637	63	2	months	month	NOUN
dti-2637	63	3	later	later	ADV
dti-2637	63	4	,	,	PUNCT
dti-2637	63	5	most	most	ADJ
dti-2637	63	6	of	of	ADP
dti-2637	63	7	the	the	DET
dti-2637	63	8	previously	previously	ADV
dti-2637	63	9	identified	identify	VERB
dti-2637	63	10	focal	focal	ADJ
dti-2637	63	11	nodules	nodule	NOUN
dti-2637	63	12	in	in	ADP
dti-2637	63	13	the	the	DET
dti-2637	63	14	lung	lung	NOUN
dti-2637	63	15	were	be	AUX
dti-2637	63	16	not	not	PART
dti-2637	63	17	clearly	clearly	ADV
dti-2637	63	18	visualized	visualize	VERB
dti-2637	63	19	by	by	ADP
dti-2637	63	20	ct	ct	PROPN
dti-2637	63	21	,	,	PUNCT
dti-2637	63	22	the	the	DET
dti-2637	63	23	remaining	remain	VERB
dti-2637	63	24	lesions	lesion	NOUN
dti-2637	63	25	decreased	decrease	VERB
dti-2637	63	26	in	in	ADP
dti-2637	63	27	size	size	NOUN
dti-2637	63	28	up	up	ADP
dti-2637	63	29	to	to	PART
dti-2637	63	30	1	1	NUM
dti-2637	63	31	-	-	SYM
dti-2637	63	32	2	2	NUM
dti-2637	63	33	mm	mm	NOUN
dti-2637	63	34	.	.	PUNCT
dti-2637	64	1	in	in	ADP
dti-2637	64	2	may	may	PROPN
dti-2637	64	3	2019	2019	NUM
dti-2637	64	4	,	,	PUNCT
dti-2637	64	5	chest	chest	NOUN
dti-2637	64	6	ct	ct	PROPN
dti-2637	64	7	scans	scan	NOUN
dti-2637	64	8	confirmed	confirm	VERB
dti-2637	64	9	the	the	DET
dti-2637	64	10	reduction	reduction	NOUN
dti-2637	64	11	of	of	ADP
dti-2637	64	12	lung	lung	NOUN
dti-2637	64	13	nodules	nodule	NOUN
dti-2637	64	14	(	(	PUNCT
dti-2637	64	15	fig	fig	NOUN
dti-2637	64	16	.	.	PUNCT
dti-2637	64	17	2b	2b	NUM
dti-2637	64	18	)	)	PUNCT
dti-2637	64	19	.	.	PUNCT
dti-2637	65	1	however	however	ADV
dti-2637	65	2	,	,	PUNCT
dti-2637	65	3	a	a	DET
dti-2637	65	4	para	para	NOUN
dti-2637	65	5	-	-	PUNCT
dti-2637	65	6	aortic	aortic	ADJ
dti-2637	65	7	lymph	lymph	NOUN
dti-2637	65	8	node	node	NOUN
dti-2637	65	9	(	(	PUNCT
dti-2637	65	10	paln	paln	NOUN
dti-2637	65	11	)	)	PUNCT
dti-2637	65	12	on	on	ADP
dti-2637	65	13	the	the	DET
dti-2637	65	14	left	left	NOUN
dti-2637	65	15	up	up	ADP
dti-2637	65	16	to	to	ADP
dti-2637	65	17	15×12	15×12	NUM
dti-2637	65	18	mm	mm	NOUN
dti-2637	65	19	was	be	AUX
dti-2637	65	20	found	find	VERB
dti-2637	65	21	(	(	PUNCT
dti-2637	65	22	fig	fig	NOUN
dti-2637	65	23	.	.	PUNCT
dti-2637	65	24	2c	2c	NUM
dti-2637	65	25	)	)	PUNCT
dti-2637	65	26	.	.	PUNCT
dti-2637	66	1	using	use	VERB
dti-2637	66	2	the	the	DET
dti-2637	66	3	irecist	irecist	NOUN
dti-2637	66	4	as	as	ADP
dti-2637	66	5	a	a	DET
dti-2637	66	6	modified	modified	ADJ
dti-2637	66	7	immune	immune	ADJ
dti-2637	66	8	recist	recist	NOUN
dti-2637	66	9	criterion	criterion	NOUN
dti-2637	66	10	(	(	PUNCT
dti-2637	66	11	10	10	NUM
dti-2637	66	12	)	)	PUNCT
dti-2637	66	13	,	,	PUNCT
dti-2637	66	14	the	the	DET
dti-2637	66	15	response	response	NOUN
dti-2637	66	16	was	be	AUX
dti-2637	66	17	classified	classify	VERB
dti-2637	66	18	as	as	ADP
dti-2637	66	19	a	a	DET
dti-2637	66	20	dissociated	dissociate	VERB
dti-2637	66	21	response	response	NOUN
dti-2637	66	22	.	.	PUNCT
dti-2637	67	1	mss	mss	PROPN
dti-2637	67	2	phenotype	phenotype	NOUN
dti-2637	67	3	in	in	ADP
dti-2637	67	4	lymph	lymph	NOUN
dti-2637	67	5	node	node	NOUN
dti-2637	67	6	was	be	AUX
dti-2637	67	7	further	far	ADV
dti-2637	67	8	verified	verify	VERB
dti-2637	67	9	by	by	ADP
dti-2637	67	10	pcr	pcr	PROPN
dti-2637	67	11	(	(	PUNCT
dti-2637	67	12	fig	fig	NOUN
dti-2637	67	13	.	.	PUNCT
dti-2637	67	14	1b	1b	NUM
dti-2637	67	15	)	)	PUNCT
dti-2637	67	16	.	.	PUNCT
dti-2637	68	1	further	further	ADJ
dti-2637	68	2	administration	administration	NOUN
dti-2637	68	3	of	of	ADP
dti-2637	68	4	nivolumab	nivolumab	NOUN
dti-2637	68	5	allowed	allow	VERB
dti-2637	68	6	achieving	achieve	VERB
dti-2637	68	7	positive	positive	ADJ
dti-2637	68	8	dynamics	dynamic	NOUN
dti-2637	68	9	in	in	ADP
dti-2637	68	10	terms	term	NOUN
dti-2637	68	11	of	of	ADP
dti-2637	68	12	the	the	DET
dti-2637	68	13	disappearance	disappearance	NOUN
dti-2637	68	14	of	of	ADP
dti-2637	68	15	lesions	lesion	NOUN
dti-2637	68	16	in	in	ADP
dti-2637	68	17	the	the	DET
dti-2637	68	18	lung	lung	NOUN
dti-2637	68	19	(	(	PUNCT
dti-2637	68	20	fig	fig	NOUN
dti-2637	68	21	.	.	PUNCT
dti-2637	69	1	2d	2d	NOUN
dti-2637	69	2	)	)	PUNCT
dti-2637	69	3	and	and	CCONJ
dti-2637	69	4	the	the	DET
dti-2637	69	5	absence	absence	NOUN
dti-2637	69	6	of	of	ADP
dti-2637	69	7	the	the	DET
dti-2637	69	8	growth	growth	NOUN
dti-2637	69	9	of	of	ADP
dti-2637	69	10	paln	paln	ADJ
dti-2637	69	11	metastases	metastasis	NOUN
dti-2637	69	12	in	in	ADP
dti-2637	69	13	august	august	PROPN
dti-2637	69	14	2019	2019	NUM
dti-2637	69	15	(	(	PUNCT
dti-2637	69	16	fig	fig	NOUN
dti-2637	69	17	.	.	PUNCT
dti-2637	70	1	2e	2e	NUM
dti-2637	70	2	)	)	PUNCT
dti-2637	70	3	.	.	PUNCT
dti-2637	71	1	an	an	DET
dti-2637	71	2	immune	immune	ADJ
dti-2637	71	3	stable	stable	ADJ
dti-2637	71	4	disease	disease	NOUN
dti-2637	71	5	(	(	PUNCT
dti-2637	71	6	isd	isd	PROPN
dti-2637	71	7	)	)	PUNCT
dti-2637	71	8	per	per	ADP
dti-2637	71	9	irecist	irecist	NOUN
dti-2637	71	10	was	be	AUX
dti-2637	71	11	recorded	record	VERB
dti-2637	71	12	until	until	ADP
dti-2637	71	13	september	september	PROPN
dti-2637	71	14	2021	2021	NUM
dti-2637	71	15	,	,	PUNCT
dti-2637	71	16	when	when	SCONJ
dti-2637	71	17	we	we	PRON
dti-2637	71	18	had	have	VERB
dti-2637	71	19	to	to	PART
dti-2637	71	20	discontinue	discontinue	VERB
dti-2637	71	21	treatment	treatment	NOUN
dti-2637	71	22	due	due	ADP
dti-2637	71	23	to	to	ADP
dti-2637	71	24	the	the	DET
dti-2637	71	25	patient	patient	NOUN
dti-2637	71	26	being	be	AUX
dti-2637	71	27	infected	infect	VERB
dti-2637	71	28	with	with	ADP
dti-2637	71	29	covid-19	covid-19	PROPN
dti-2637	71	30	.	.	PUNCT
dti-2637	72	1	the	the	DET
dti-2637	72	2	administration	administration	NOUN
dti-2637	72	3	of	of	ADP
dti-2637	72	4	nivolumab	nivolumab	NOUN
dti-2637	72	5	was	be	AUX
dti-2637	72	6	resumed	resume	VERB
dti-2637	72	7	;	;	PUNCT
dti-2637	73	1	fig	fig	NOUN
dti-2637	73	2	.	.	NOUN
dti-2637	73	3	2	2	NUM
dti-2637	73	4	chest	chest	NOUN
dti-2637	73	5	computed	compute	VERB
dti-2637	73	6	tomography	tomography	NOUN
dti-2637	73	7	(	(	PUNCT
dti-2637	73	8	ct	ct	NOUN
dti-2637	73	9	)	)	PUNCT
dti-2637	73	10	of	of	ADP
dti-2637	73	11	the	the	DET
dti-2637	73	12	lung	lung	NOUN
dti-2637	73	13	lesions	lesion	NOUN
dti-2637	73	14	and	and	CCONJ
dti-2637	73	15	para	para	NOUN
dti-2637	73	16	-	-	PUNCT
dti-2637	73	17	aortic	aortic	ADJ
dti-2637	73	18	lymph	lymph	NOUN
dti-2637	73	19	node	node	ADJ
dti-2637	73	20	lesion	lesion	NOUN
dti-2637	73	21	.	.	PUNCT
dti-2637	74	1	focal	focal	ADJ
dti-2637	74	2	nodules	nodule	NOUN
dti-2637	74	3	in	in	ADP
dti-2637	74	4	the	the	DET
dti-2637	74	5	lung	lung	NOUN
dti-2637	74	6	at	at	ADP
dti-2637	74	7	start	start	NOUN
dti-2637	74	8	of	of	ADP
dti-2637	74	9	nivolumab	nivolumab	NOUN
dti-2637	74	10	treatment	treatment	NOUN
dti-2637	74	11	(	(	PUNCT
dti-2637	74	12	a	a	NOUN
dti-2637	74	13	)	)	PUNCT
dti-2637	74	14	;	;	PUNCT
dti-2637	74	15	5	5	NUM
dti-2637	74	16	months	month	NOUN
dti-2637	74	17	after	after	ADP
dti-2637	74	18	nivolumab	nivolumab	NOUN
dti-2637	74	19	treatment	treatment	NOUN
dti-2637	74	20	,	,	PUNCT
dti-2637	74	21	reduction	reduction	NOUN
dti-2637	74	22	of	of	ADP
dti-2637	74	23	lung	lung	NOUN
dti-2637	74	24	nodules	nodule	NOUN
dti-2637	74	25	(	(	PUNCT
dti-2637	74	26	b	b	NOUN
dti-2637	74	27	)	)	PUNCT
dti-2637	74	28	and	and	CCONJ
dti-2637	74	29	para	para	NOUN
dti-2637	74	30	-	-	PUNCT
dti-2637	74	31	aortic	aortic	ADJ
dti-2637	74	32	lymph	lymph	NOUN
dti-2637	74	33	node	node	NOUN
dti-2637	74	34	lesion	lesion	NOUN
dti-2637	74	35	up	up	ADP
dti-2637	74	36	to	to	PART
dti-2637	74	37	12	12	NUM
dti-2637	74	38	mm	mm	NOUN
dti-2637	74	39	(	(	PUNCT
dti-2637	74	40	c	c	NOUN
dti-2637	74	41	)	)	PUNCT
dti-2637	74	42	;	;	PUNCT
dti-2637	74	43	8	8	NUM
dti-2637	74	44	months	month	NOUN
dti-2637	74	45	after	after	ADP
dti-2637	74	46	nivolumab	nivolumab	NOUN
dti-2637	74	47	treatment	treatment	NOUN
dti-2637	74	48	,	,	PUNCT
dti-2637	74	49	disappearance	disappearance	NOUN
dti-2637	74	50	of	of	ADP
dti-2637	74	51	lung	lung	NOUN
dti-2637	74	52	lesions	lesion	NOUN
dti-2637	74	53	(	(	PUNCT
dti-2637	74	54	d	d	NOUN
dti-2637	74	55	)	)	PUNCT
dti-2637	74	56	and	and	CCONJ
dti-2637	74	57	lack	lack	NOUN
dti-2637	74	58	of	of	ADP
dti-2637	74	59	growth	growth	NOUN
dti-2637	74	60	of	of	ADP
dti-2637	74	61	para	para	NOUN
dti-2637	74	62	-	-	PUNCT
dti-2637	74	63	aortic	aortic	ADJ
dti-2637	74	64	lymph	lymph	NOUN
dti-2637	74	65	node	node	NOUN
dti-2637	74	66	lesion	lesion	NOUN
dti-2637	74	67	(	(	PUNCT
dti-2637	74	68	e	e	NOUN
dti-2637	74	69	)	)	PUNCT
dti-2637	74	70	;	;	PUNCT
dti-2637	74	71	increase	increase	NOUN
dti-2637	74	72	of	of	ADP
dti-2637	74	73	para	para	NOUN
dti-2637	74	74	-	-	PUNCT
dti-2637	74	75	aortic	aortic	ADJ
dti-2637	74	76	lymph	lymph	NOUN
dti-2637	74	77	node	node	ADJ
dti-2637	74	78	lesion	lesion	NOUN
dti-2637	74	79	40	40	NUM
dti-2637	74	80	months	month	NOUN
dti-2637	74	81	after	after	ADP
dti-2637	74	82	nivolumab	nivolumab	NOUN
dti-2637	74	83	treatment	treatment	NOUN
dti-2637	74	84	(	(	PUNCT
dti-2637	74	85	f	f	NOUN
dti-2637	74	86	)	)	PUNCT
dti-2637	74	87	.	.	PUNCT
dti-2637	75	1	babyshkina	babyshkina	PROPN
dti-2637	75	2	et	et	PROPN
dti-2637	75	3	al	al	PROPN
dti-2637	75	4	drug	drug	PROPN
dti-2637	75	5	target	target	NOUN
dti-2637	75	6	insights	insight	NOUN
dti-2637	75	7	2024	2024	NUM
dti-2637	75	8	;	;	PUNCT
dti-2637	75	9	18	18	NUM
dti-2637	75	10	:	:	SYM
dti-2637	75	11	7	7	NUM
dti-2637	75	12	©	©	ADP
dti-2637	75	13	2024	2024	NUM
dti-2637	75	14	the	the	DET
dti-2637	75	15	authors	author	NOUN
dti-2637	75	16	.	.	PUNCT
dti-2637	76	1	published	publish	VERB
dti-2637	76	2	by	by	ADP
dti-2637	76	3	aboutscience	aboutscience	NOUN
dti-2637	76	4	www.aboutscience.eu	www.aboutscience.eu	NOUN
dti-2637	76	5	however	however	ADV
dti-2637	76	6	,	,	PUNCT
dti-2637	76	7	in	in	ADP
dti-2637	76	8	april	april	PROPN
dti-2637	76	9	2022	2022	NUM
dti-2637	76	10	,	,	PUNCT
dti-2637	76	11	ct	ct	PROPN
dti-2637	76	12	scans	scan	NOUN
dti-2637	76	13	revealed	reveal	VERB
dti-2637	76	14	an	an	DET
dti-2637	76	15	increase	increase	NOUN
dti-2637	76	16	in	in	ADP
dti-2637	76	17	the	the	DET
dti-2637	76	18	size	size	NOUN
dti-2637	76	19	of	of	ADP
dti-2637	76	20	paln	paln	NOUN
dti-2637	76	21	by	by	ADP
dti-2637	76	22	7	7	NUM
dti-2637	76	23	mm	mm	NOUN
dti-2637	76	24	compared	compare	VERB
dti-2637	76	25	with	with	ADP
dti-2637	76	26	the	the	DET
dti-2637	76	27	baseline	baseline	NOUN
dti-2637	76	28	(	(	PUNCT
dti-2637	76	29	fig	fig	NOUN
dti-2637	76	30	.	.	PUNCT
dti-2637	76	31	2f	2f	NUM
dti-2637	76	32	)	)	PUNCT
dti-2637	76	33	.	.	PUNCT
dti-2637	77	1	the	the	DET
dti-2637	77	2	decision	decision	NOUN
dti-2637	77	3	to	to	PART
dti-2637	77	4	initiate	initiate	VERB
dti-2637	77	5	folfox	folfox	PROPN
dti-2637	77	6	plus	plus	CCONJ
dti-2637	77	7	bevacizumab	bevacizumab	NOUN
dti-2637	77	8	therapy	therapy	NOUN
dti-2637	77	9	(	(	PUNCT
dti-2637	77	10	bevacizumab	bevacizumab	NOUN
dti-2637	77	11	5	5	NUM
dti-2637	77	12	mg	mg	PROPN
dti-2637	77	13	/	/	SYM
dti-2637	77	14	kg	kg	NOUN
dti-2637	77	15	on	on	ADP
dti-2637	77	16	day	day	NOUN
dti-2637	77	17	1	1	NUM
dti-2637	77	18	,	,	PUNCT
dti-2637	77	19	oxaliplatin	oxaliplatin	NOUN
dti-2637	77	20	85	85	NUM
dti-2637	77	21	mg	mg	NUM
dti-2637	77	22	/	/	SYM
dti-2637	77	23	m2	m2	PROPN
dti-2637	77	24	on	on	ADP
dti-2637	77	25	day	day	NOUN
dti-2637	77	26	1	1	NUM
dti-2637	77	27	,	,	PUNCT
dti-2637	77	28	leucovorin	leucovorin	NOUN
dti-2637	77	29	400	400	NUM
dti-2637	77	30	mg	mg	PROPN
dti-2637	77	31	/	/	SYM
dti-2637	77	32	m2	m2	PROPN
dti-2637	77	33	on	on	ADP
dti-2637	77	34	day	day	NOUN
dti-2637	77	35	1	1	NUM
dti-2637	77	36	,	,	PUNCT
dti-2637	77	37	and	and	CCONJ
dti-2637	77	38	5	5	NUM
dti-2637	77	39	-	-	PUNCT
dti-2637	77	40	fluorouracil	fluorouracil	NOUN
dti-2637	77	41	400	400	NUM
dti-2637	77	42	mg	mg	NUM
dti-2637	77	43	/	/	SYM
dti-2637	77	44	m2	m2	PROPN
dti-2637	77	45	bolus	bolus	ADJ
dti-2637	77	46	injection	injection	NOUN
dti-2637	77	47	followed	follow	VERB
dti-2637	77	48	by	by	ADP
dti-2637	77	49	48	48	NUM
dti-2637	77	50	hours	hour	NOUN
dti-2637	77	51	continuous	continuous	ADJ
dti-2637	77	52	infusion	infusion	NOUN
dti-2637	77	53	of	of	ADP
dti-2637	77	54	5	5	NUM
dti-2637	77	55	-	-	PUNCT
dti-2637	77	56	fluorouracil	fluorouracil	NOUN
dti-2637	77	57	2,400	2,400	NUM
dti-2637	77	58	mg	mg	PROPN
dti-2637	77	59	/	/	SYM
dti-2637	77	60	m2	m2	PROPN
dti-2637	77	61	on	on	ADP
dti-2637	77	62	day	day	NOUN
dti-2637	77	63	1	1	NUM
dti-2637	77	64	)	)	PUNCT
dti-2637	77	65	was	be	AUX
dti-2637	77	66	taken	take	VERB
dti-2637	77	67	by	by	ADP
dti-2637	77	68	a	a	DET
dti-2637	77	69	multidisciplinary	multidisciplinary	ADJ
dti-2637	77	70	staff	staff	NOUN
dti-2637	77	71	.	.	PUNCT
dti-2637	78	1	due	due	ADP
dti-2637	78	2	to	to	ADP
dti-2637	78	3	the	the	DET
dti-2637	78	4	experience	experience	NOUN
dti-2637	78	5	of	of	ADP
dti-2637	78	6	hypersensitivity	hypersensitivity	NOUN
dti-2637	78	7	reaction	reaction	NOUN
dti-2637	78	8	to	to	ADP
dti-2637	78	9	oxaliplatin	oxaliplatin	NOUN
dti-2637	78	10	after	after	ADP
dti-2637	78	11	three	three	NUM
dti-2637	78	12	cycles	cycle	NOUN
dti-2637	78	13	,	,	PUNCT
dti-2637	78	14	the	the	DET
dti-2637	78	15	patient	patient	NOUN
dti-2637	78	16	was	be	AUX
dti-2637	78	17	switched	switch	VERB
dti-2637	78	18	to	to	ADP
dti-2637	78	19	the	the	DET
dti-2637	78	20	bevacizumab	bevacizumab	NOUN
dti-2637	78	21	in	in	ADP
dti-2637	78	22	combination	combination	NOUN
dti-2637	78	23	with	with	ADP
dti-2637	78	24	capecitabine	capecitabine	NOUN
dti-2637	78	25	regimen	regiman	NOUN
dti-2637	78	26	(	(	PUNCT
dti-2637	78	27	bevacizumab	bevacizumab	NOUN
dti-2637	78	28	5	5	NUM
dti-2637	78	29	mg	mg	NUM
dti-2637	78	30	/	/	SYM
dti-2637	78	31	kg	kg	NOUN
dti-2637	78	32	and	and	CCONJ
dti-2637	78	33	capecitabine	capecitabine	VERB
dti-2637	78	34	2,500	2,500	NUM
dti-2637	78	35	mg	mg	NUM
dti-2637	78	36	/	/	SYM
dti-2637	78	37	day	day	NOUN
dti-2637	78	38	,	,	PUNCT
dti-2637	78	39	days	day	NOUN
dti-2637	78	40	1	1	NUM
dti-2637	78	41	and	and	CCONJ
dti-2637	78	42	14	14	NUM
dti-2637	78	43	)	)	PUNCT
dti-2637	78	44	.	.	PUNCT
dti-2637	79	1	currently	currently	ADV
dti-2637	79	2	,	,	PUNCT
dti-2637	79	3	the	the	DET
dti-2637	79	4	patient	patient	NOUN
dti-2637	79	5	has	have	AUX
dti-2637	79	6	completed	complete	VERB
dti-2637	79	7	10	10	NUM
dti-2637	79	8	cycles	cycle	NOUN
dti-2637	79	9	of	of	ADP
dti-2637	79	10	this	this	DET
dti-2637	79	11	therapy	therapy	NOUN
dti-2637	79	12	with	with	ADP
dti-2637	79	13	good	good	ADJ
dti-2637	79	14	tolerance	tolerance	NOUN
dti-2637	79	15	.	.	PUNCT
dti-2637	80	1	conclusion	conclusion	NOUN
dti-2637	80	2	we	we	PRON
dti-2637	80	3	have	have	AUX
dti-2637	80	4	reported	report	VERB
dti-2637	80	5	a	a	DET
dti-2637	80	6	patient	patient	NOUN
dti-2637	80	7	with	with	ADP
dti-2637	80	8	mss	mss	PROPN
dti-2637	80	9	/	/	SYM
dti-2637	80	10	pmmr	pmmr	PROPN
dti-2637	80	11	mcrc	mcrc	NOUN
dti-2637	80	12	who	who	PRON
dti-2637	80	13	has	have	AUX
dti-2637	80	14	achieved	achieve	VERB
dti-2637	80	15	a	a	DET
dti-2637	80	16	complete	complete	ADJ
dti-2637	80	17	response	response	NOUN
dti-2637	80	18	to	to	ADP
dti-2637	80	19	nivolumab	nivolumab	NOUN
dti-2637	80	20	after	after	ADP
dti-2637	80	21	a	a	DET
dti-2637	80	22	progression	progression	NOUN
dti-2637	80	23	on	on	ADP
dti-2637	80	24	chemotherapy	chemotherapy	NOUN
dti-2637	80	25	and	and	CCONJ
dti-2637	80	26	antiangiogenic	antiangiogenic	ADJ
dti-2637	80	27	treatment	treatment	NOUN
dti-2637	80	28	,	,	PUNCT
dti-2637	80	29	with	with	ADP
dti-2637	80	30	a	a	DET
dti-2637	80	31	response	response	NOUN
dti-2637	80	32	duration	duration	NOUN
dti-2637	80	33	of	of	ADP
dti-2637	80	34	32	32	NUM
dti-2637	80	35	months	month	NOUN
dti-2637	80	36	.	.	PUNCT
dti-2637	81	1	based	base	VERB
dti-2637	81	2	on	on	ADP
dti-2637	81	3	the	the	DET
dti-2637	81	4	presence	presence	NOUN
dti-2637	81	5	of	of	ADP
dti-2637	81	6	pd	pd	PROPN
dti-2637	81	7	-	-	PROPN
dti-2637	81	8	l1	l1	PROPN
dti-2637	81	9	weak	weak	ADJ
dti-2637	81	10	expression	expression	NOUN
dti-2637	81	11	,	,	PUNCT
dti-2637	81	12	the	the	DET
dti-2637	81	13	potential	potential	ADJ
dti-2637	81	14	immunogenic	immunogenic	ADJ
dti-2637	81	15	features	feature	NOUN
dti-2637	81	16	of	of	ADP
dti-2637	81	17	the	the	DET
dti-2637	81	18	tumor	tumor	NOUN
dti-2637	81	19	leading	lead	VERB
dti-2637	81	20	to	to	PART
dti-2637	81	21	benefit	benefit	VERB
dti-2637	81	22	from	from	ADP
dti-2637	81	23	pd-1	pd-1	ADP
dti-2637	81	24	/	/	SYM
dti-2637	81	25	pd	pd	NOUN
dti-2637	81	26	-	-	PROPN
dti-2637	81	27	l1	l1	PROPN
dti-2637	81	28	targeting	target	VERB
dti-2637	81	29	therapy	therapy	NOUN
dti-2637	81	30	could	could	AUX
dti-2637	81	31	be	be	AUX
dti-2637	81	32	suggested	suggest	VERB
dti-2637	81	33	.	.	PUNCT
dti-2637	82	1	present	present	ADJ
dti-2637	82	2	case	case	NOUN
dti-2637	82	3	report	report	NOUN
dti-2637	82	4	demonstrates	demonstrate	VERB
dti-2637	82	5	that	that	SCONJ
dti-2637	82	6	a	a	DET
dti-2637	82	7	subset	subset	NOUN
dti-2637	82	8	of	of	ADP
dti-2637	82	9	pretreated	pretreate	VERB
dti-2637	82	10	mcrc	mcrc	NOUN
dti-2637	82	11	patients	patient	NOUN
dti-2637	82	12	with	with	ADP
dti-2637	82	13	mss	mss	PROPN
dti-2637	82	14	/	/	SYM
dti-2637	82	15	pmmr	pmmr	ADJ
dti-2637	82	16	phenotype	phenotype	NOUN
dti-2637	82	17	may	may	AUX
dti-2637	82	18	benefit	benefit	VERB
dti-2637	82	19	from	from	ADP
dti-2637	82	20	nivolumab	nivolumab	NOUN
dti-2637	82	21	.	.	PUNCT
dti-2637	83	1	we	we	PRON
dti-2637	83	2	will	will	AUX
dti-2637	83	3	undertake	undertake	VERB
dti-2637	83	4	a	a	DET
dti-2637	83	5	high	high	ADJ
dti-2637	83	6	-	-	PUNCT
dti-2637	83	7	throughput	throughput	NOUN
dti-2637	83	8	transcriptome	transcriptome	ADJ
dti-2637	83	9	sequencing	sequencing	NOUN
dti-2637	83	10	of	of	ADP
dti-2637	83	11	both	both	DET
dti-2637	83	12	colon	colon	NOUN
dti-2637	83	13	tumor	tumor	NOUN
dti-2637	83	14	and	and	CCONJ
dti-2637	83	15	lymph	lymph	NOUN
dti-2637	83	16	node	node	ADJ
dti-2637	83	17	specimens	specimen	NOUN
dti-2637	83	18	to	to	PART
dti-2637	83	19	establish	establish	VERB
dti-2637	83	20	possible	possible	ADJ
dti-2637	83	21	molecular	molecular	ADJ
dti-2637	83	22	background	background	NOUN
dti-2637	83	23	for	for	ADP
dti-2637	83	24	a	a	DET
dti-2637	83	25	dissociated	dissociate	VERB
dti-2637	83	26	response	response	NOUN
dti-2637	83	27	.	.	PUNCT
dti-2637	84	1	disclosures	disclosure	NOUN
dti-2637	84	2	conflict	conflict	NOUN
dti-2637	84	3	of	of	ADP
dti-2637	84	4	interest	interest	NOUN
dti-2637	84	5	:	:	PUNCT
dti-2637	84	6	the	the	DET
dti-2637	84	7	authors	author	NOUN
dti-2637	84	8	have	have	VERB
dti-2637	84	9	no	no	DET
dti-2637	84	10	conflicts	conflict	NOUN
dti-2637	84	11	of	of	ADP
dti-2637	84	12	interest	interest	NOUN
dti-2637	84	13	to	to	PART
dti-2637	84	14	declare	declare	VERB
dti-2637	84	15	that	that	PRON
dti-2637	84	16	are	be	AUX
dti-2637	84	17	relevant	relevant	ADJ
dti-2637	84	18	to	to	ADP
dti-2637	84	19	the	the	DET
dti-2637	84	20	content	content	NOUN
dti-2637	84	21	of	of	ADP
dti-2637	84	22	this	this	DET
dti-2637	84	23	article	article	NOUN
dti-2637	84	24	.	.	PUNCT
dti-2637	85	1	ethical	ethical	ADJ
dti-2637	85	2	approval	approval	NOUN
dti-2637	85	3	:	:	PUNCT
dti-2637	85	4	this	this	DET
dti-2637	85	5	study	study	NOUN
dti-2637	85	6	was	be	AUX
dti-2637	85	7	performed	perform	VERB
dti-2637	85	8	in	in	ADP
dti-2637	85	9	line	line	NOUN
dti-2637	85	10	with	with	ADP
dti-2637	85	11	the	the	DET
dti-2637	85	12	principles	principle	NOUN
dti-2637	85	13	of	of	ADP
dti-2637	85	14	the	the	DET
dti-2637	85	15	helsinki	helsinki	PROPN
dti-2637	85	16	declaration	declaration	PROPN
dti-2637	85	17	.	.	PUNCT
dti-2637	86	1	approval	approval	NOUN
dti-2637	86	2	was	be	AUX
dti-2637	86	3	granted	grant	VERB
dti-2637	86	4	by	by	ADP
dti-2637	86	5	the	the	DET
dti-2637	86	6	ethics	ethic	NOUN
dti-2637	86	7	committee	committee	PROPN
dti-2637	86	8	of	of	ADP
dti-2637	86	9	the	the	DET
dti-2637	86	10	cancer	cancer	NOUN
dti-2637	86	11	research	research	PROPN
dti-2637	86	12	institute	institute	PROPN
dti-2637	86	13	,	,	PUNCT
dti-2637	86	14	tomsk	tomsk	PROPN
dti-2637	86	15	national	national	PROPN
dti-2637	86	16	research	research	PROPN
dti-2637	86	17	medical	medical	ADJ
dti-2637	86	18	center	center	NOUN
dti-2637	86	19	(	(	PUNCT
dti-2637	86	20	date	date	NOUN
dti-2637	86	21	:	:	PUNCT
dti-2637	86	22	01/19/22	01/19/22	PROPN
dti-2637	86	23	)	)	PUNCT
dti-2637	86	24	.	.	PUNCT
dti-2637	87	1	informed	informed	ADJ
dti-2637	87	2	consent	consent	NOUN
dti-2637	87	3	:	:	PUNCT
dti-2637	87	4	written	write	VERB
dti-2637	87	5	informed	informed	ADJ
dti-2637	87	6	consent	consent	NOUN
dti-2637	87	7	was	be	AUX
dti-2637	87	8	obtained	obtain	VERB
dti-2637	87	9	from	from	ADP
dti-2637	87	10	the	the	DET
dti-2637	87	11	patient	patient	NOUN
dti-2637	87	12	.	.	PUNCT
dti-2637	88	1	financial	financial	ADJ
dti-2637	88	2	support	support	NOUN
dti-2637	88	3	:	:	PUNCT
dti-2637	88	4	the	the	DET
dti-2637	88	5	study	study	NOUN
dti-2637	88	6	was	be	AUX
dti-2637	88	7	supported	support	VERB
dti-2637	88	8	by	by	ADP
dti-2637	88	9	the	the	DET
dti-2637	88	10	russian	russian	PROPN
dti-2637	88	11	science	science	PROPN
dti-2637	88	12	foundation	foundation	PROPN
dti-2637	88	13	,	,	PUNCT
dti-2637	88	14	grant	grant	VERB
dti-2637	88	15	#	#	SYM
dti-2637	88	16	22	22	NUM
dti-2637	88	17	-	-	SYM
dti-2637	88	18	15	15	NUM
dti-2637	88	19	-	-	SYM
dti-2637	88	20	00212	00212	NUM
dti-2637	88	21	;	;	PUNCT
dti-2637	88	22	online	online	ADJ
dti-2637	88	23	.	.	PUNCT
dti-2637	89	1	author	author	NOUN
dti-2637	89	2	contributions	contribution	NOUN
dti-2637	89	3	all	all	DET
dti-2637	89	4	authors	author	NOUN
dti-2637	89	5	contributed	contribute	VERB
dti-2637	89	6	to	to	ADP
dti-2637	89	7	the	the	DET
dti-2637	89	8	study	study	NOUN
dti-2637	89	9	conception	conception	NOUN
dti-2637	89	10	and	and	CCONJ
dti-2637	89	11	design	design	NOUN
dti-2637	89	12	.	.	PUNCT
dti-2637	90	1	material	material	NOUN
dti-2637	90	2	preparation	preparation	NOUN
dti-2637	90	3	,	,	PUNCT
dti-2637	90	4	data	data	NOUN
dti-2637	90	5	collection	collection	NOUN
dti-2637	90	6	,	,	PUNCT
dti-2637	90	7	and	and	CCONJ
dti-2637	90	8	analysis	analysis	NOUN
dti-2637	90	9	were	be	AUX
dti-2637	90	10	performed	perform	VERB
dti-2637	90	11	by	by	ADP
dti-2637	90	12	evgeny	evgeny	PROPN
dti-2637	90	13	grigoryev	grigoryev	PROPN
dti-2637	90	14	,	,	PUNCT
dti-2637	90	15	tatyana	tatyana	PROPN
dti-2637	90	16	dronova	dronova	PROPN
dti-2637	90	17	,	,	PUNCT
dti-2637	90	18	polina	polina	PROPN
dti-2637	90	19	gervas	gervas	PROPN
dti-2637	90	20	,	,	PUNCT
dti-2637	90	21	alexey	alexey	PROPN
dti-2637	90	22	dobrodeev	dobrodeev	PROPN
dti-2637	90	23	,	,	PUNCT
dti-2637	90	24	dmitry	dmitry	PROPN
dti-2637	90	25	kostromitskiy	kostromitskiy	PROPN
dti-2637	90	26	,	,	PUNCT
dti-2637	90	27	victor	victor	PROPN
dti-2637	90	28	goldberg	goldberg	PROPN
dti-2637	90	29	,	,	PUNCT
dti-2637	90	30	and	and	CCONJ
dti-2637	90	31	sergey	sergey	PROPN
dti-2637	90	32	afanasiev	afanasiev	PROPN
dti-2637	90	33	.	.	PUNCT
dti-2637	91	1	the	the	DET
dti-2637	91	2	first	first	ADJ
dti-2637	91	3	draft	draft	NOUN
dti-2637	91	4	of	of	ADP
dti-2637	91	5	the	the	DET
dti-2637	91	6	manuscript	manuscript	NOUN
dti-2637	91	7	was	be	AUX
dti-2637	91	8	written	write	VERB
dti-2637	91	9	by	by	ADP
dti-2637	91	10	nataliya	nataliya	PROPN
dti-2637	91	11	babyshkina	babyshkina	PROPN
dti-2637	91	12	and	and	CCONJ
dti-2637	91	13	nataliya	nataliya	NOUN
dti-2637	91	14	popova	popova	PROPN
dti-2637	91	15	,	,	PUNCT
dti-2637	91	16	and	and	CCONJ
dti-2637	91	17	all	all	DET
dti-2637	91	18	authors	author	NOUN
dti-2637	91	19	commented	comment	VERB
dti-2637	91	20	on	on	ADP
dti-2637	91	21	previous	previous	ADJ
dti-2637	91	22	versions	version	NOUN
dti-2637	91	23	of	of	ADP
dti-2637	91	24	the	the	DET
dti-2637	91	25	manuscript	manuscript	NOUN
dti-2637	91	26	.	.	PUNCT
dti-2637	92	1	all	all	DET
dti-2637	92	2	authors	author	NOUN
dti-2637	92	3	read	read	VERB
dti-2637	92	4	and	and	CCONJ
dti-2637	92	5	approved	approve	VERB
dti-2637	92	6	the	the	DET
dti-2637	92	7	final	final	ADJ
dti-2637	92	8	manuscript	manuscript	NOUN
dti-2637	92	9	.	.	PUNCT
dti-2637	93	1	references	reference	NOUN
dti-2637	93	2	1	1	NUM
dti-2637	93	3	.	.	PUNCT
dti-2637	94	1	xiao	xiao	PROPN
dti-2637	94	2	y	y	PROPN
dti-2637	94	3	,	,	PUNCT
dti-2637	94	4	freeman	freeman	PROPN
dti-2637	94	5	gj	gj	PROPN
dti-2637	94	6	.	.	PUNCT
dti-2637	95	1	the	the	DET
dti-2637	95	2	microsatellite	microsatellite	ADJ
dti-2637	95	3	instable	instable	ADJ
dti-2637	95	4	subset	subset	NOUN
dti-2637	95	5	of	of	ADP
dti-2637	95	6	colorectal	colorectal	ADJ
dti-2637	95	7	cancer	cancer	NOUN
dti-2637	95	8	is	be	AUX
dti-2637	95	9	a	a	DET
dti-2637	95	10	particularly	particularly	ADV
dti-2637	95	11	good	good	ADJ
dti-2637	95	12	candidate	candidate	NOUN
dti-2637	95	13	for	for	ADP
dti-2637	95	14	checkpoint	checkpoint	NOUN
dti-2637	95	15	blockade	blockade	NOUN
dti-2637	95	16	immunotherapy	immunotherapy	NOUN
dti-2637	95	17	.	.	PUNCT
dti-2637	96	1	cancer	cancer	NOUN
dti-2637	96	2	discov	discov	NOUN
dti-2637	96	3	.	.	PUNCT
dti-2637	97	1	2015;5(1):16	2015;5(1):16	NUM
dti-2637	97	2	-	-	SYM
dti-2637	97	3	18	18	NUM
dti-2637	97	4	.	.	PUNCT
dti-2637	98	1	crossref	crossref	PROPN
dti-2637	98	2	pubmed	pubmed	PROPN
dti-2637	98	3	2	2	PROPN
dti-2637	98	4	.	.	PUNCT
dti-2637	99	1	overman	overman	PROPN
dti-2637	99	2	mj	mj	PROPN
dti-2637	99	3	,	,	PUNCT
dti-2637	99	4	mcdermott	mcdermott	PROPN
dti-2637	99	5	r	r	PROPN
dti-2637	99	6	,	,	PUNCT
dti-2637	99	7	leach	leach	NOUN
dti-2637	99	8	jl	jl	NOUN
dti-2637	99	9	,	,	PUNCT
dti-2637	99	10	et	et	PROPN
dti-2637	99	11	al	al	PROPN
dti-2637	99	12	.	.	PROPN
dti-2637	99	13	nivolumab	nivolumab	PROPN
dti-2637	99	14	in	in	ADP
dti-2637	99	15	patients	patient	NOUN
dti-2637	99	16	with	with	ADP
dti-2637	99	17	metastatic	metastatic	ADJ
dti-2637	99	18	dna	dna	PROPN
dti-2637	99	19	mismatch	mismatch	NOUN
dti-2637	99	20	repair	repair	NOUN
dti-2637	99	21	-	-	PUNCT
dti-2637	99	22	deficient	deficient	ADJ
dti-2637	99	23	or	or	CCONJ
dti-2637	99	24	microsatellite	microsatellite	ADJ
dti-2637	99	25	instability	instability	NOUN
dti-2637	99	26	-	-	PUNCT
dti-2637	99	27	high	high	ADJ
dti-2637	99	28	colorectal	colorectal	ADJ
dti-2637	99	29	cancer	cancer	NOUN
dti-2637	99	30	(	(	PUNCT
dti-2637	99	31	checkmate	checkmate	VERB
dti-2637	99	32	142	142	NUM
dti-2637	99	33	):	):	PUNCT
dti-2637	99	34	an	an	DET
dti-2637	99	35	open	open	ADJ
dti-2637	99	36	-	-	PUNCT
dti-2637	99	37	label	label	NOUN
dti-2637	99	38	,	,	PUNCT
dti-2637	99	39	multicentre	multicentre	NOUN
dti-2637	99	40	,	,	PUNCT
dti-2637	99	41	phase	phase	NOUN
dti-2637	99	42	2	2	NUM
dti-2637	99	43	study	study	NOUN
dti-2637	99	44	.	.	PUNCT
dti-2637	100	1	lancet	lancet	PROPN
dti-2637	100	2	oncol	oncol	PROPN
dti-2637	100	3	.	.	PUNCT
dti-2637	101	1	2017;18(9):1182	2017;18(9):1182	PROPN
dti-2637	101	2	-	-	PUNCT
dti-2637	101	3	1191	1191	NUM
dti-2637	101	4	.	.	PUNCT
dti-2637	102	1	crossref	crossref	PROPN
dti-2637	102	2	pubmed	pubmed	PROPN
dti-2637	102	3	3	3	PROPN
dti-2637	102	4	.	.	PUNCT
dti-2637	103	1	overman	overman	PROPN
dti-2637	103	2	mj	mj	PROPN
dti-2637	103	3	,	,	PUNCT
dti-2637	103	4	bergamo	bergamo	X
dti-2637	103	5	f	f	PROPN
dti-2637	103	6	,	,	PUNCT
dti-2637	103	7	mcdermott	mcdermott	PROPN
dti-2637	103	8	rs	rs	PROPN
dti-2637	103	9	,	,	PUNCT
dti-2637	103	10	et	et	PROPN
dti-2637	103	11	al	al	PROPN
dti-2637	103	12	.	.	PROPN
dti-2637	103	13	nivolumab	nivolumab	PROPN
dti-2637	103	14	in	in	ADP
dti-2637	103	15	patients	patient	NOUN
dti-2637	103	16	with	with	ADP
dti-2637	103	17	dna	dna	PROPN
dti-2637	103	18	mismatch	mismatch	NOUN
dti-2637	103	19	repair	repair	NOUN
dti-2637	103	20	-	-	PUNCT
dti-2637	103	21	deficient	deficient	ADJ
dti-2637	103	22	/	/	SYM
dti-2637	103	23	microsatellite	microsatellite	NOUN
dti-2637	103	24	instability	instability	NOUN
dti-2637	103	25	-	-	PUNCT
dti-2637	103	26	high	high	ADJ
dti-2637	103	27	(	(	PUNCT
dti-2637	103	28	dmmr	dmmr	NOUN
dti-2637	103	29	/	/	SYM
dti-2637	103	30	msi	msi	PROPN
dti-2637	103	31	-	-	NOUN
dti-2637	103	32	h	h	NOUN
dti-2637	103	33	)	)	PUNCT
dti-2637	103	34	metastatic	metastatic	ADJ
dti-2637	103	35	colorectal	colorectal	ADJ
dti-2637	103	36	cancer	cancer	NOUN
dti-2637	103	37	(	(	PUNCT
dti-2637	103	38	mcrc	mcrc	NOUN
dti-2637	103	39	):	):	PUNCT
dti-2637	103	40	long	long	ADJ
dti-2637	103	41	-	-	PUNCT
dti-2637	103	42	term	term	NOUN
dti-2637	103	43	survival	survival	NOUN
dti-2637	103	44	according	accord	VERB
dti-2637	103	45	to	to	ADP
dti-2637	103	46	prior	prior	ADJ
dti-2637	103	47	line	line	NOUN
dti-2637	103	48	of	of	ADP
dti-2637	103	49	treatment	treatment	NOUN
dti-2637	103	50	from	from	ADP
dti-2637	103	51	checkmate-142	checkmate-142	NOUN
dti-2637	103	52	.	.	PUNCT
dti-2637	104	1	j	j	PROPN
dti-2637	104	2	clin	clin	PROPN
dti-2637	104	3	oncol	oncol	PROPN
dti-2637	104	4	.	.	PUNCT
dti-2637	105	1	2018;36(4_suppl	2018;36(4_suppl	NOUN
dti-2637	105	2	):	):	PUNCT
dti-2637	105	3	554–554	554–554	NUM
dti-2637	105	4	.	.	PUNCT
dti-2637	106	1	crossref	crossref	PROPN
dti-2637	106	2	4	4	NUM
dti-2637	106	3	.	.	PUNCT
dti-2637	106	4	fakih	fakih	PROPN
dti-2637	106	5	m	m	PROPN
dti-2637	106	6	,	,	PUNCT
dti-2637	106	7	raghav	raghav	PROPN
dti-2637	106	8	kps	kps	PROPN
dti-2637	106	9	,	,	PUNCT
dti-2637	106	10	chang	chang	PROPN
dti-2637	106	11	dz	dz	PROPN
dti-2637	106	12	,	,	PUNCT
dti-2637	106	13	et	et	PROPN
dti-2637	106	14	al	al	PROPN
dti-2637	106	15	.	.	PROPN
dti-2637	106	16	regorafenib	regorafenib	PROPN
dti-2637	106	17	plus	plus	CCONJ
dti-2637	106	18	nivolumab	nivolumab	NOUN
dti-2637	106	19	in	in	ADP
dti-2637	106	20	patients	patient	NOUN
dti-2637	106	21	with	with	ADP
dti-2637	106	22	mismatch	mismatch	ADJ
dti-2637	106	23	repair	repair	NOUN
dti-2637	106	24	-	-	PUNCT
dti-2637	106	25	proficient	proficient	ADJ
dti-2637	106	26	/	/	SYM
dti-2637	106	27	microsatellite	microsatellite	ADJ
dti-2637	106	28	stable	stable	ADJ
dti-2637	106	29	metastatic	metastatic	ADJ
dti-2637	106	30	colorectal	colorectal	ADJ
dti-2637	106	31	cancer	cancer	NOUN
dti-2637	106	32	:	:	PUNCT
dti-2637	106	33	a	a	DET
dti-2637	106	34	single	single	ADJ
dti-2637	106	35	-	-	PUNCT
dti-2637	106	36	arm	arm	NOUN
dti-2637	106	37	,	,	PUNCT
dti-2637	106	38	open	open	ADJ
dti-2637	106	39	-	-	PUNCT
dti-2637	106	40	label	label	NOUN
dti-2637	106	41	,	,	PUNCT
dti-2637	106	42	multicentre	multicentre	NOUN
dti-2637	106	43	phase	phase	NOUN
dti-2637	106	44	2	2	NUM
dti-2637	106	45	study	study	NOUN
dti-2637	106	46	.	.	PUNCT
dti-2637	107	1	eclinicalmedicine	eclinicalmedicine	PROPN
dti-2637	107	2	.	.	PUNCT
dti-2637	108	1	2023;58:101917	2023;58:101917	X
dti-2637	108	2	.	.	PUNCT
dti-2637	109	1	crossref	crossref	PROPN
dti-2637	109	2	pubmed	pubmed	PROPN
dti-2637	109	3	5	5	PROPN
dti-2637	109	4	.	.	PUNCT
dti-2637	110	1	saunders	saunders	PROPN
dti-2637	110	2	mp	mp	PROPN
dti-2637	110	3	,	,	PUNCT
dti-2637	110	4	graham	graham	PROPN
dti-2637	110	5	j	j	PROPN
dti-2637	110	6	,	,	PUNCT
dti-2637	110	7	cunningham	cunningham	PROPN
dti-2637	110	8	d	d	PROPN
dti-2637	110	9	,	,	PUNCT
dti-2637	110	10	et	et	PROPN
dti-2637	110	11	al	al	PROPN
dti-2637	110	12	.	.	PUNCT
dti-2637	111	1	cxd101	cxd101	PROPN
dti-2637	111	2	and	and	CCONJ
dti-2637	111	3	nivolumab	nivolumab	NOUN
dti-2637	111	4	in	in	ADP
dti-2637	111	5	patients	patient	NOUN
dti-2637	111	6	with	with	ADP
dti-2637	111	7	metastatic	metastatic	ADJ
dti-2637	111	8	microsatellite	microsatellite	ADJ
dti-2637	111	9	-	-	PUNCT
dti-2637	111	10	stable	stable	ADJ
dti-2637	111	11	colorectal	colorectal	ADJ
dti-2637	111	12	cancer	cancer	NOUN
dti-2637	111	13	(	(	PUNCT
dti-2637	111	14	carosell	carosell	ADJ
dti-2637	111	15	):	):	PUNCT
dti-2637	111	16	a	a	DET
dti-2637	111	17	multicentre	multicentre	NOUN
dti-2637	111	18	,	,	PUNCT
dti-2637	111	19	open	open	ADJ
dti-2637	111	20	-	-	PUNCT
dti-2637	111	21	label	label	NOUN
dti-2637	111	22	,	,	PUNCT
dti-2637	111	23	single	single	ADJ
dti-2637	111	24	-	-	PUNCT
dti-2637	111	25	arm	arm	NOUN
dti-2637	111	26	,	,	PUNCT
dti-2637	111	27	phase	phase	NOUN
dti-2637	111	28	ii	ii	NOUN
dti-2637	111	29	trial	trial	NOUN
dti-2637	111	30	.	.	PUNCT
dti-2637	112	1	esmo	esmo	NOUN
dti-2637	112	2	open	open	ADJ
dti-2637	112	3	.	.	PUNCT
dti-2637	113	1	2022;7(6):100594	2022;7(6):100594	X
dti-2637	113	2	.	.	PUNCT
dti-2637	114	1	crossref	crossref	PROPN
dti-2637	114	2	pubmed	pubmed	PROPN
dti-2637	114	3	6	6	NUM
dti-2637	114	4	.	.	PUNCT
dti-2637	115	1	humbert	humbert	PROPN
dti-2637	115	2	o	o	PROPN
dti-2637	115	3	,	,	PUNCT
dti-2637	115	4	chardin	chardin	VERB
dti-2637	115	5	d.	d.	PROPN
dti-2637	115	6	dissociated	dissociate	VERB
dti-2637	115	7	response	response	NOUN
dti-2637	115	8	in	in	ADP
dti-2637	115	9	metastatic	metastatic	ADJ
dti-2637	115	10	cancer	cancer	NOUN
dti-2637	115	11	:	:	PUNCT
dti-2637	115	12	an	an	DET
dti-2637	115	13	atypical	atypical	ADJ
dti-2637	115	14	pattern	pattern	NOUN
dti-2637	115	15	brought	bring	VERB
dti-2637	115	16	into	into	ADP
dti-2637	115	17	the	the	DET
dti-2637	115	18	spotlight	spotlight	NOUN
dti-2637	115	19	with	with	ADP
dti-2637	115	20	immunotherapy	immunotherapy	NOUN
dti-2637	115	21	.	.	PUNCT
dti-2637	116	1	front	front	ADJ
dti-2637	116	2	oncol	oncol	ADJ
dti-2637	116	3	.	.	PUNCT
dti-2637	117	1	2020;10:566297	2020;10:566297	NUM
dti-2637	117	2	.	.	PUNCT
dti-2637	117	3	crossref	crossref	PROPN
dti-2637	117	4	pubmed	pubmed	PROPN
dti-2637	117	5	7	7	PROPN
dti-2637	117	6	.	.	PUNCT
dti-2637	118	1	wong	wong	PROPN
dti-2637	118	2	a	a	PRON
dti-2637	118	3	,	,	PUNCT
dti-2637	118	4	vellayappan	vellayappan	NOUN
dti-2637	118	5	b	b	PROPN
dti-2637	118	6	,	,	PUNCT
dti-2637	118	7	cheng	cheng	PROPN
dti-2637	118	8	l	l	PROPN
dti-2637	118	9	,	,	PUNCT
dti-2637	118	10	et	et	PROPN
dti-2637	118	11	al	al	PROPN
dti-2637	118	12	.	.	PUNCT
dti-2637	119	1	atypical	atypical	ADJ
dti-2637	119	2	response	response	NOUN
dti-2637	119	3	patterns	pattern	NOUN
dti-2637	119	4	in	in	ADP
dti-2637	119	5	renal	renal	ADJ
dti-2637	119	6	cell	cell	NOUN
dti-2637	119	7	carcinoma	carcinoma	NOUN
dti-2637	119	8	treated	treat	VERB
dti-2637	119	9	with	with	ADP
dti-2637	119	10	immune	immune	ADJ
dti-2637	119	11	checkpoint	checkpoint	NOUN
dti-2637	119	12	inhibitors	inhibitor	NOUN
dti-2637	119	13	-	-	PUNCT
dti-2637	119	14	navigating	navigate	VERB
dti-2637	119	15	the	the	DET
dti-2637	119	16	radiologic	radiologic	ADJ
dti-2637	119	17	potpourri	potpourri	NOUN
dti-2637	119	18	.	.	PUNCT
dti-2637	120	1	cancers	cancer	NOUN
dti-2637	120	2	(	(	PUNCT
dti-2637	120	3	basel	basel	PROPN
dti-2637	120	4	)	)	PUNCT
dti-2637	120	5	.	.	PUNCT
dti-2637	121	1	2021;13(7):1689	2021;13(7):1689	NUM
dti-2637	121	2	.	.	PUNCT
dti-2637	122	1	crossref	crossref	PROPN
dti-2637	122	2	pubmed	pubmed	PROPN
dti-2637	122	3	8	8	PROPN
dti-2637	122	4	.	.	PUNCT
dti-2637	123	1	tazdait	tazdait	PROPN
dti-2637	123	2	m	m	PROPN
dti-2637	123	3	,	,	PUNCT
dti-2637	123	4	mezquita	mezquita	PROPN
dti-2637	123	5	l	l	PROPN
dti-2637	123	6	,	,	PUNCT
dti-2637	123	7	lahmar	lahmar	PROPN
dti-2637	123	8	j	j	PROPN
dti-2637	123	9	,	,	PUNCT
dti-2637	123	10	et	et	PROPN
dti-2637	123	11	al	al	PROPN
dti-2637	123	12	.	.	PUNCT
dti-2637	123	13	patterns	pattern	NOUN
dti-2637	123	14	of	of	ADP
dti-2637	123	15	responses	response	NOUN
dti-2637	123	16	in	in	ADP
dti-2637	123	17	metastatic	metastatic	ADJ
dti-2637	123	18	nsclc	nsclc	NOUN
dti-2637	123	19	during	during	ADP
dti-2637	123	20	pd-1	pd-1	ADP
dti-2637	123	21	or	or	CCONJ
dti-2637	123	22	pdl-1	pdl-1	ADV
dti-2637	123	23	inhibitor	inhibitor	NOUN
dti-2637	123	24	therapy	therapy	NOUN
dti-2637	123	25	:	:	PUNCT
dti-2637	123	26	comparison	comparison	NOUN
dti-2637	123	27	of	of	ADP
dti-2637	123	28	recist	recist	NOUN
dti-2637	123	29	1.1	1.1	NUM
dti-2637	123	30	,	,	PUNCT
dti-2637	123	31	irrecist	irrecist	ADJ
dti-2637	123	32	and	and	CCONJ
dti-2637	123	33	irecist	irecist	ADJ
dti-2637	123	34	criteria	criterion	NOUN
dti-2637	123	35	.	.	PUNCT
dti-2637	124	1	eur	eur	PROPN
dti-2637	124	2	j	j	PROPN
dti-2637	124	3	cancer	cancer	NOUN
dti-2637	124	4	.	.	PUNCT
dti-2637	125	1	2018;88:38	2018;88:38	NUM
dti-2637	125	2	-	-	SYM
dti-2637	125	3	47	47	NUM
dti-2637	125	4	.	.	PUNCT
dti-2637	126	1	crossref	crossref	PROPN
dti-2637	126	2	pubmed	pubmed	PROPN
dti-2637	126	3	9	9	NUM
dti-2637	126	4	.	.	PUNCT
dti-2637	127	1	sato	sato	PROPN
dti-2637	127	2	y	y	PROPN
dti-2637	127	3	,	,	PUNCT
dti-2637	127	4	morimoto	morimoto	PROPN
dti-2637	127	5	t	t	PROPN
dti-2637	127	6	,	,	PUNCT
dti-2637	127	7	hara	hara	PROPN
dti-2637	127	8	s	s	PROPN
dti-2637	127	9	,	,	PUNCT
dti-2637	127	10	et	et	PROPN
dti-2637	127	11	al	al	PROPN
dti-2637	127	12	.	.	PROPN
dti-2637	127	13	dissociated	dissociate	VERB
dti-2637	127	14	response	response	NOUN
dti-2637	127	15	and	and	CCONJ
dti-2637	127	16	clinical	clinical	ADJ
dti-2637	127	17	benefit	benefit	NOUN
dti-2637	127	18	in	in	ADP
dti-2637	127	19	patients	patient	NOUN
dti-2637	127	20	treated	treat	VERB
dti-2637	127	21	with	with	ADP
dti-2637	127	22	nivolumab	nivolumab	NOUN
dti-2637	127	23	monotherapy	monotherapy	NOUN
dti-2637	127	24	.	.	PUNCT
dti-2637	128	1	invest	invest	VERB
dti-2637	128	2	new	new	ADJ
dti-2637	128	3	drugs	drug	NOUN
dti-2637	128	4	.	.	PUNCT
dti-2637	129	1	2021;39(4):1170	2021;39(4):1170	NUM
dti-2637	129	2	-	-	SYM
dti-2637	129	3	1178	1178	NUM
dti-2637	129	4	.	.	PUNCT
dti-2637	130	1	crossref	crossref	PROPN
dti-2637	130	2	pubmed	pubmed	PROPN
dti-2637	130	3	10	10	PROPN
dti-2637	130	4	.	.	PUNCT
dti-2637	131	1	seymour	seymour	PROPN
dti-2637	131	2	l	l	PROPN
dti-2637	131	3	,	,	PUNCT
dti-2637	131	4	bogaerts	bogaerts	PROPN
dti-2637	131	5	j	j	PROPN
dti-2637	131	6	,	,	PUNCT
dti-2637	131	7	perrone	perrone	PROPN
dti-2637	131	8	a	a	X
dti-2637	131	9	,	,	PUNCT
dti-2637	131	10	et	et	PROPN
dti-2637	131	11	al	al	PROPN
dti-2637	131	12	;	;	PUNCT
dti-2637	131	13	recist	recist	NOUN
dti-2637	131	14	working	working	NOUN
dti-2637	131	15	group	group	NOUN
dti-2637	131	16	.	.	PUNCT
dti-2637	132	1	irecist	irecist	PROPN
dti-2637	132	2	:	:	PUNCT
dti-2637	133	1	guidelines	guideline	NOUN
dti-2637	133	2	for	for	ADP
dti-2637	133	3	response	response	NOUN
dti-2637	133	4	criteria	criterion	NOUN
dti-2637	133	5	for	for	ADP
dti-2637	133	6	use	use	NOUN
dti-2637	133	7	in	in	ADP
dti-2637	133	8	trials	trial	NOUN
dti-2637	133	9	testing	testing	NOUN
dti-2637	133	10	immunotherapeutics	immunotherapeutic	NOUN
dti-2637	133	11	.	.	PUNCT
dti-2637	134	1	lancet	lancet	PROPN
dti-2637	134	2	oncol	oncol	PROPN
dti-2637	134	3	.	.	PUNCT
dti-2637	135	1	2017;18(3):e143	2017;18(3):e143	NOUN
dti-2637	135	2	-	-	PUNCT
dti-2637	135	3	e152	e152	PROPN
dti-2637	135	4	.	.	PUNCT
dti-2637	136	1	crossref	crossref	PROPN
dti-2637	136	2	pubmed	pubmed	PROPN
dti-2637	136	3	https://rscf.ru/en/project/22-15-00212/	https://rscf.ru/en/project/22-15-00212/	PROPN
dti-2637	137	1	https://doi.org/10.1158/2159-8290.cd-14-1397	https://doi.org/10.1158/2159-8290.cd-14-1397	PROPN
dti-2637	137	2	https://www.ncbi.nlm.nih.gov/pubmed/25583798	https://www.ncbi.nlm.nih.gov/pubmed/25583798	NUM
dti-2637	137	3	https://doi.org/10.1016/s1470-2045(17)30422-9	https://doi.org/10.1016/s1470-2045(17)30422-9	NOUN
dti-2637	137	4	https://www.ncbi.nlm.nih.gov/pubmed/28734759	https://www.ncbi.nlm.nih.gov/pubmed/28734759	PRON
dti-2637	137	5	https://doi.org/10.1200/jco.2018.36.4_suppl.554	https://doi.org/10.1200/jco.2018.36.4_suppl.554	X
dti-2637	137	6	https://doi.org/10.1016/j.eclinm.2023.101917	https://doi.org/10.1016/j.eclinm.2023.101917	NOUN
dti-2637	137	7	https://www.ncbi.nlm.nih.gov/pubmed/37090438	https://www.ncbi.nlm.nih.gov/pubmed/37090438	NUM
dti-2637	137	8	https://doi.org/10.1016/j.esmoop.2022.100594	https://doi.org/10.1016/j.esmoop.2022.100594	PROPN
dti-2637	137	9	https://www.ncbi.nlm.nih.gov/pubmed/36327756	https://www.ncbi.nlm.nih.gov/pubmed/36327756	NUM
dti-2637	137	10	https://doi.org/10.3389/fonc.2020.566297	https://doi.org/10.3389/fonc.2020.566297	PROPN
dti-2637	137	11	https://www.ncbi.nlm.nih.gov/pubmed/33072599	https://www.ncbi.nlm.nih.gov/pubmed/33072599	NUM
dti-2637	137	12	https://doi.org/10.3390/cancers13071689	https://doi.org/10.3390/cancers13071689	NOUN
dti-2637	137	13	https://www.ncbi.nlm.nih.gov/pubmed/33918397	https://www.ncbi.nlm.nih.gov/pubmed/33918397	NUM
dti-2637	137	14	https://doi.org/10.1016/j.ejca.2017.10.017	https://doi.org/10.1016/j.ejca.2017.10.017	X
dti-2637	137	15	https://www.ncbi.nlm.nih.gov/pubmed/29182990	https://www.ncbi.nlm.nih.gov/pubmed/29182990	NOUN
dti-2637	137	16	https://doi.org/10.1007/s10637-021-01077-7	https://doi.org/10.1007/s10637-021-01077-7	PROPN
dti-2637	137	17	https://www.ncbi.nlm.nih.gov/pubmed/33566254	https://www.ncbi.nlm.nih.gov/pubmed/33566254	NUM
dti-2637	137	18	https://doi.org/10.1016/s1470-2045(17)30074-8	https://doi.org/10.1016/s1470-2045(17)30074-8	PROPN
dti-2637	137	19	https://www.ncbi.nlm.nih.gov/pubmed/28271869	https://www.ncbi.nlm.nih.gov/pubmed/28271869	NUM